Characteristics, Treatments, and Outcomes of Patients W
Hospitalized for Heart Failure

Journal of the American College of Cardiology

50, 768-777

DOI: 10.1016/j.jacc.2007.04.064

Citation Report

#	Article	IF	Citations
2	Can We Predict and Prevent the Onset of Acute Decompensated Heart Failure?. Circulation, 2007, 116, 1526-1529.	1.6	17
3	The nature of heart failure as a challenge to the integration of palliative care services. Current Opinion in Supportive and Palliative Care, 2007, 1, 249-254.	1.3	22
4	Epidemiology, Pathophysiology, andÂPrognosis of Heart Failure in the Elderly. Heart Failure Clinics, 2007, 3, 381-387.	2.1	64
5	Acute heart failure syndromes: Potential strategies to improve post-discharge outcomes. Current Treatment Options in Cardiovascular Medicine, 2008, 10, 349-357.	0.9	2
6	Heart failure in women: An equal opportunity player in the expanding epidemic of heart failure. Current Cardiovascular Risk Reports, 2008, 2, 210-216.	2.0	0
7	Hospitalized patients with acute decompensated heart failure: Recognition, risk stratification, and treatment review. Journal of Hospital Medicine, 2008, 3, S16-S24.	1.4	9
8	Â¿QuÃ© ha cambiado en CardiologÃa en el Ãºltimo aÃ±o? Implicaciones para la prÃ¡ctica clÃnica. Revista Clinica Espanola, 2008, 208, 3-8.	0.6	0
9	In-hospital mortality and prognostic factors in patients admitted for new-onset heart failure with preserved or reduced ejection fraction: a prospective observational study. Archives of Cardiovascular Diseases, 2008, 101, 226-234.	1.6	14
10	Acute Heart Failure Syndromes and Coronary Perfusion. Journal of the American College of Cardiology, 2008, 52, 13-16.	2.8	43
11	Diastolic Dysfunction. Journal of the American College of Cardiology, 2008, 52, 1022-1023.	2.8	1
12	Heart Failure With Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2008, 300, 431.	7.4	154
13	Clinical Outcome of Patients with Heart Failure and Preserved Left Ventricular Function. American Journal of Medicine, 2008, 121, 997-1001.	1.5	30
15	Cardiorenal Syndrome. Journal of the American College of Cardiology, 2008, 52, 1527-1539.	2.8	1,669
16	Heart Failure Care in the Outpatient Cardiology Practice Setting. Circulation: Heart Failure, 2008, 1, 98-106.	3.9	168
17	Measuring Quality in Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2008, 1, 9-11.	2.2	19
18	Statistical Models and Patient Predictors of Readmission for Heart Failure<subtitle>A Systematic Review</subtitle>. Archives of Internal Medicine, 2008, 168, 1371.	3.8	303
20	Heart failure with preserved ejection fraction: Clinical characteristics of 4133 patients enrolled in the Iâ€PRESERVE trial. European Journal of Heart Failure, 2008, 10, 149-156.	7.1	183
21	Management of Heart Failure. , 2008, , .		1

#	Article	IF	Citations
22	Influence of coronary artery disease and coronary revascularization status on outcomes in patients with acute heart failure syndromes: A report from OPTIMIZEâ€HF (Organized Program to Initiate) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 7 2008, 10, 1215-1223.	7.1	60
23	Hypertension, Heart Failure, and Ejection Fraction. Circulation, 2008, 118, 2223-2223.	1.6	12
24	State of the art: Using natriuretic peptide levels in clinical practice. European Journal of Heart Failure, 2008, 10, 824-839.	7.1	691
25	Acute Decompensated Heart Failure. , 0, , 190-199.		1
26	Diagnosis Of Heart Failure With Preserved Ejection Fraction. Methodist DeBakey Cardiovascular Journal, 2008, 4, 8-12.	1.0	1
27	Hospitalization. , 2009, , 197-214.		0
29	Society of Chest Pain Centers recommendations for the evaluation and management of the observation stay acute heart failure patientâ€"part 1. Acute Cardiac Care, 2009, 11, 3-42.	0.2	43
30	Cardiorenal syndrome: biomarkers linking kidney damage with heart failure. Biomarkers in Medicine, 2009, 3, 549-560.	1.4	12
31	Investigational Positive Inotropic Agents for Acute Heart Failure. Cardiovascular & Hematological Disorders Drug Targets, 2009, 9, 193-205.	0.7	17
32	Acute heart failure syndromes: Epidemiology, risk stratification and prognostic factors. Acute Cardiac Care, 2009, 11, 77-82.	0.2	6
33	Factors Associated With Neurologically Intact Survival for Patients With Acute Heart Failure and In-Hospital Cardiac Arrest. Circulation: Heart Failure, 2009, 2, 572-581.	3.9	22
34	Irbesartan for Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine, 2009, 360, 1256-1259.	27.0	0
35	The prognostic significance of heart failure with preserved left ventricular ejection fraction: a literatureâ€based metaâ€analysis. European Journal of Heart Failure, 2009, 11, 855-862.	7.1	114
36	Importance of Treadmill Exercise Time as an Initial Prognostic Screening Tool in Patients With Systolic Left Ventricular Dysfunction. Circulation, 2009, 119, 3189-3197.	1.6	50
37	Rationale and design of the Karolinskaâ€Rennes (KaRen) prospective study of dyssynchrony in heart failure with preserved ejection fraction. European Journal of Heart Failure, 2009, 11, 198-204.	7.1	47
38	The Cardiorenal Syndrome. Blood Purification, 2009, 27, 114-126.	1.8	71
39	Representativeness of a National Heart Failure Quality-of-Care Registry. Circulation: Cardiovascular Quality and Outcomes, 2009, 2, 377-384.	2.2	82
40	Comparison of Acute Electrocardiographic Presentation in Patients With Diastolic vs Systolic Heart Failure. Congestive Heart Failure, 2009, 15, 165-169.	2.0	2

#	Article	IF	Citations
41	Initial Emergency Department Systolic Blood Pressure Predicts Left Ventricular Systolic Function in Acute Decompensated Heart Failure. Congestive Heart Failure, 2009, 15, 9-13.	2.0	5
42	A Propensity-Matched Study of Elevated Jugular Venous Pressure and Outcomes in Chronic Heart Failure. American Journal of Cardiology, 2009, 103, 839-844.	1.6	20
43	Usefulness of a Combination of Systolic Function by Left Ventricular Ejection Fraction and Diastolic Function by E/Eâ€² to Predict Prognosis in Patients With Heart Failure. American Journal of Cardiology, 2009, 103, 1275-1279.	1.6	51
44	Distribution of Left Ventricular Ejection Fraction in Patients With Ischemic and Hypertensive Heart Disease and Chronic Heart Failure. American Journal of Cardiology, 2009, 104, 1413-1415.	1.6	25
45	A novel approach to improve cardiac performance: cardiac myosin activators. Heart Failure Reviews, 2009, 14, 289-298.	3.9	122
46	Therapy for acute heart failure syndromes. Current Cardiology Reports, 2009, 11, 192-201.	2.9	7
47	Cardiorenal syndrome in children with heart failure. Current Heart Failure Reports, 2009, 6, 191-198.	3.3	12
48	Heart Failure with Normal Ejection Fraction. Herz, 2009, 34, 89-96.	1.1	27
49	Depressive symptoms increase risk of rehospitalisation in heart failure patients with preserved systolic function. Journal of Clinical Nursing, 2009, 18, 1871-1877.	3.0	28
50	Prevalence and Physiological Predictors of Sleep Apnea in Patients With Heart Failure and Systolic Dysfunction. Journal of Cardiac Failure, 2009, 15, 279-285.	1.7	217
51	The Rationale for an Acute Heart Failure Syndromes Clinical Trials Network. Journal of Cardiac Failure, 2009, 15, 467-474.	1.7	24
53	Influence of patient age and sex on delivery of guideline-recommended heart failure care in the outpatient cardiology practice setting: Findings from IMPROVE HF. American Heart Journal, 2009, 157, 754-762.e2.	2.7	93
54	Cystatin C in Acute Heart Failure Without Advanced Renal Impairment. American Journal of Medicine, 2009, 122, 566-573.	1.5	66
55	Acute Heart Failure Syndromes in Patients With Coronary Artery Disease. Journal of the American College of Cardiology, 2009, 53, 254-263.	2.8	124
56	Acute Heart Failure Syndromes. Journal of the American College of Cardiology, 2009, 53, 557-573.	2.8	515
57	N-Terminal Proâ€"B-Type Natriuretic Peptide-Guided Treatment for Chronic Heart Failure. Journal of the American College of Cardiology, 2009, 55, 53-60.	2.8	319
59	Mechanisms of the cardiorenal syndromes. Nature Reviews Nephrology, 2009, 5, 641-649.	9.6	69
60	Special Cases in Acute Heart Failure Syndromes: Atrial Fibrillation and Wide Complex Tachycardia. Heart Failure Clinics, 2009, 5, 113-123.	2.1	2

#	Article	IF	Citations
61	Management of hypertension in chronic heart failure. Expert Review of Cardiovascular Therapy, 2009, 7, 423-433.	1.5	11
63	Diastolic dysfunction and heart failure with preserved ejection fraction: rationale for RAAS antagonist/CCB combination therapy. Journal of the American Society of Hypertension, 2009, 3, 52-68.	2.3	3
64	Heart Failure and the Emergency Department: Epidemiology, Characteristics, and Outcomes. Heart Failure Clinics, 2009, 5, 1-7.	2.1	4
65	Cardiorenal Syndrome in Acute Decompensated Heart Failure. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 2013-2026.	4.5	140
66	The challenges associated with current clinical trials for diastolic heart failure. Current Opinion in Cardiology, 2009, 24, 230-238.	1.8	8
67	Cardiorenal syndromes. Current Opinion in Critical Care, 2009, 15, 384-391.	3.2	29
68	Management of left ventricular diastolic heart failure: is it only blood pressure control?. Current Opinion in Cardiology, 2009, 24, 161-166.	1.8	8
69	Long Term Prognosis of Chronic Heart Failure Reduced vs Preserved Left Ventricular Ejection Fraction. Circulation Journal, 2009, 73, 92-99.	1.6	41
70	Characteristics and Outcomes of Hospitalized Patients With Heart Failure and Reduced vs Preserved Ejection Fraction A Report From the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circulation Journal, 2009, 73, 1893-1900.	1.6	290
71	Additive prognostic value of cardiopulmonary exercise testing in elderly patients with heart failure. Clinical Science, 2009, 116, 415-422.	4.3	11
72	New Investigational Drugs for the Management of Acute Heart Failure Syndromes. Current Medicinal Chemistry, 2010, 17, 363-390.	2.4	13
73	Risk factors and comorbidities in a community-wide sample of patients hospitalized with acute systolic or diastolic heart failure: The Worcester Heart Failure Study. Coronary Artery Disease, 2010, 21, 137-143.	0.7	13
74	Interventions for treating peripartum cardiomyopathy to improve outcomes for women and babies. The Cochrane Library, 2010, , CD008589.	2.8	15
75	Heart failure in the elderly: diastolic heart failure, medical therapy, women and end-of-life care. Aging Health, 2010, 6, 429-437.	0.3	0
76	Metabolic Syndrome and Heart Failure. Circulation Journal, 2010, 74, 2550-2551.	1.6	1
77	Multi-modality imaging of diastolic function. Journal of Nuclear Cardiology, 2010, 17, 316-327.	2.1	14
78	Evolving Approaches to the Management of Heart Failure with Preserved Ejection Fraction in Patients with Coronary Artery Disease. Current Treatment Options in Cardiovascular Medicine, 2010, 12, 58-75.	0.9	27
79	Myocardial Ischemia in Patients with Diastolic Dysfunction and Heart Failure. Current Cardiology Reports, 2010, 12, 216-222.	2.9	28

#	Article	IF	Citations
80	Exercise in the Management of Patients with Chronic Heart Failure. Current Heart Failure Reports, 2010, 7, 35-41.	3.3	12
81	Role and benefits of exercise in the management of patients with heart failure. Heart Failure Reviews, 2010, 15, 523-530.	3.9	22
82	Clinical characteristics and outcomes of heart failure with preserved ejection fraction: Lessons from epidemiological studies. Journal of Cardiology, 2010, 55, 13-22.	1.9	44
83	Effect of Beta-Blocker Therapy on Rehospitalization Rates in Women Versus Men With Heart Failure and Preserved Ejection Fraction. American Journal of Cardiology, 2010, 105, 229-234.	1.6	41
84	Telmisartan Improves Morphologic and Functional Changes in Both Left Ventricular Myocardium and Carotid Arterial Wall in Patients with Hypertension: Assessment by Tissue Doppler Imaging and Carotid Ultrasonography. Echocardiography, 2010, 27, 864-872.	0.9	16
85	Signs and Symptoms of Heart Failure: Are You Asking the Right Questions?. American Journal of Critical Care, 2010, 19, 443-452.	1.6	69
86	Acute Heart Failure Syndromes: Emergency Department Presentation, Treatment, and Disposition: Current Approaches and Future Aims. Circulation, 2010, 122, 1975-1996.	1.6	239
87	Mode of Death in Patients With Heart Failure and a Preserved Ejection Fraction. Circulation, 2010, 121, 1393-1405.	1.6	290
88	Cardiac resynchronization therapy may benefit patients with left ventricular ejection fraction >35%: a PROSPECT trial substudy. European Journal of Heart Failure, 2010, 12, 581-587.	7.1	108
89	International variations in the clinical, diagnostic, and treatment characteristics of emergency department patients with acute heart failure syndromes. European Journal of Heart Failure, 2010, 12, 1253-1260.	7.1	54
90	Critical elements of clinical followâ€up after hospital discharge for heart failure: insights from the EVEREST trial. European Journal of Heart Failure, 2010, 12, 367-374.	7.1	78
91	High prevalence of left ventricular hypertrophy in octogenarian women: The Jerusalem Longitudinal Cohort Study. Blood Pressure, 2010, 19, 86-91.	1.5	3
92	Diastolic stress testing: a new trick to evaluate the ageing heart. Heart, 2010, 96, 906-907.	2.9	2
93	Acute Heart Failure Treatment: Traditional and New Drugs. Contributions To Nephrology, 2010, 165, 112-128.	1.1	3
94	Extracorporeal Fluid Removal in Heart Failure Patients. Contributions To Nephrology, 2010, 164, 173-198.	1.1	3
95	Cardiorenal Syndromes: An Executive Summary from the Consensus Conference of the Acute Dialysis Quality Initiative (ADQI). Contributions To Nephrology, 2010, 165, 54-67.	1.1	106
96	Natriuretic peptide-guided management of patients with heart failure: a decade of progress but still a controversy. Future Cardiology, 2010, 6, 743-747.	1.2	3
97	Heart failure in the elderly: advances and challenges. Expert Review of Cardiovascular Therapy, 2010, 8, 695-715.	1.5	22

#	Article	IF	Citations
98	Treatment of Heart Failure With Normal Ejection Fraction. Journal of the American College of Cardiology, 2010, 55, 526-537.	2.8	238
99	Diastolic heart failure in elderly: The prognostic factors and interventions regarding heart failure with preserved ejection fraction. International Journal of Cardiology, 2010, 138, 311-313.	1.7	6
100	Ultrafiltration is Associated With Fewer Rehospitalizations than Continuous Diuretic Infusion in Patients With Decompensated Heart Failure: Results From UNLOAD. Journal of Cardiac Failure, 2010, 16, 277-284.	1.7	130
101	Section 4: Evaluation of Patients for Ventricular Dysfunction and Heart Failure. Journal of Cardiac Failure, 2010, 16, e44-e56.	1.7	3
102	Section 11: Evaluation and Management of Patients with Heart Failure and Preserved Left Ventricular Ejection Fraction. Journal of Cardiac Failure, 2010, 16, e126-e133.	1.7	3
103	Prevalence and prognosis of left ventricular diastolic dysfunction in the elderly: The PROTEGER Study. American Heart Journal, 2010, 160, 471-478.	2.7	25
104	Left ventricular dysfunction as a risk factor for cardiovascular and noncardiovascular hospitalizations in African Americans. American Heart Journal, 2010, 160, 488-495.	2.7	8
105	ADQI 7: the clinical management of the Cardio-Renal syndromes: work group statements from the 7th ADQI consensus conference. Nephrology Dialysis Transplantation, 2010, 25, 2077-2089.	0.7	35
106	Diagnosis and management of adults with chronic heart failure: summary of updated NICE guidance. BMJ: British Medical Journal, 2010, 341, c4130-c4130.	2.3	38
107	Epidemiology and risk profile of heart failure. Nature Reviews Cardiology, 2011, 8, 30-41.	13.7	1,608
109	Chronic Heart Failure in Older Adults. Medical Clinics of North America, 2011, 95, 439-461.	2.5	15
110	Acute Heart Failure Syndromes: Initial Management. Emergency Medicine Clinics of North America, 2011, 29, 675-688.	1.2	2
111	Effects of Treatment on Exercise Tolerance, Cardiac Function, and Mortality in Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2011, 57, 1676-1686.	2.8	128
112	A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes. JAMA - Journal of the American Medical Association, 2011, 305, 1702.	7.4	48
113	Ultrafiltration in heart failure. American Heart Journal, 2011, 161, 439-449.	2.7	30
114	Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. American Heart Journal, 2011, 161, 1024-1030.e3.	2.7	196
115	Hypertensive heart failure: patient characteristics, treatment, and outcomes. American Journal of Emergency Medicine, 2011, 29, 855-862.	1.6	37
116	Design of the Multi-Sensor Monitoring in Congestive Heart Failure (MUSIC) Study: Prospective Trial to Assess the Utility ofÂContinuous Wireless Physiologic Monitoring in Heart Failure. Journal of Cardiac Failure, 2011, 17, 11-16.	1.7	28

#	Article	IF	Citations
117	Hospitalization Epidemic in Patients With Heart Failure: Risk Factors, Risk Prediction, Knowledge Gaps, and Future Directions. Journal of Cardiac Failure, 2011, 17, 54-75.	1.7	240
118	The Impact of Extra Cardiac Comorbidities on Pressure Volume Relations in Heart Failure and Preserved Ejection Fraction. Journal of Cardiac Failure, 2011, 17, 547-555.	1.7	33
119	Association Between Prehospital Time Interval and Short-Term Outcome in Acute Heart Failure Patients. Journal of Cardiac Failure, 2011, 17, 742-747.	1.7	54
120	Low Systolic Blood Pressure at Admission Predicts Long-Term Mortality in Heart Failure With Preserved Ejection Fraction. Journal of Cardiac Failure, 2011, 17, 907-915.	1.7	32
121	PronÃ³stico de los pacientes con insuficiencia cardiaca y fracciÃ³n de eyecciÃ³n preservada. Â¿Es el mismo que con fracciÃ³n de eyecciÃ³n baja?. Revista Espanola De Cardiologia, 2011, 64, 646-648.	1.2	5
122	Novel therapeutic targets for the treatment of heart failure. Nature Reviews Drug Discovery, 2011, 10, 536-555.	46.4	125
123	Prognosis for Patients With Heart Failure With Preserved Ejection Fraction. Is It the Same As Low Ejection Fraction?. Revista Espanola De Cardiologia (English Ed), 2011, 64, 646-648.	0.6	2
124	Primary prevention of diastolic dysfunction in the normal heart: The â€œEyes Wide Shutâ€•on a statin pleiotropic effect?. Atherosclerosis, 2011, 216, 272-274.	0.8	0
125	Implantable cardioverter defibrillators and cardiac resynchronisation therapy. Lancet, The, 2011, 378, 722-730.	13.7	45
126	Diuretics as pathogenetic treatment for heart failure. International Journal of General Medicine, 2011, 4, 91.	1.8	5
127	InsuficiÃªncia cardÃaca com fraÃ§Ã£o de ejeÃ§Ã£o preservada: combater equÃvocos para uma nova abordagem. Arquivos Brasileiros De Cardiologia, 2011, 96, 504-514.	0.8	25
128	Heart Failure as a Consequence of Ischemic Heart Disease. , 2011, , 355-371.		0
129	Key role of congestion in natural history of heart failure. International Journal of General Medicine, 2011, 4, 585.	1.8	9
130	Epidemiology of Heart Failure. , 2011, , 346-354.		0
131	Aging and scleroderma. Aging Health, 2011, 7, 231-242.	0.3	1
132	Ultrafiltration is Associated With Fewer Rehospitalizations than Continuous Diuretic Infusion in Patients With Decompensated Heart Failure: Results From UNLOAD. Yearbook of Cardiology, 2011, 2011, 311-314.	0.0	0
133	Age and Preoperative Total Bilirubin Level Can Stratify Prognosis After Extracorporeal Pulsatile Left Ventricular Assist Device Implantation. Circulation Journal, 2011, 75, 121-128.	1.6	32
134	Chronic kidney disease and heart failureâ€"Bidirectional close link and common therapeutic goal. Journal of Cardiology, 2011, 57, 8-17.	1.9	94

#	Article	IF	Citations
135	Exercise Training in Congestive Heart Failure: Risks and Benefits. Progress in Cardiovascular Diseases, 2011, 53, 419-428.	3.1	56
136	Clinical Characteristics and Predictors of In-Hospital Mortality in Acute Heart Failure With Preserved Left Ventricular Ejection Fraction. American Journal of Cardiology, 2011, 107, 79-84.	1.6	38
137	A Propensity-Matched Study of the Comparative Effectiveness of Angiotensin Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors in Heart Failure Patients Age â‰¥65 Years. American Journal of Cardiology, 2011, 108, 1443-1448.	1.6	11
138	Cardio-renal syndromes: from foggy bottoms to sunny hills. Heart Failure Reviews, 2011, 16, 509-517.	3.9	6
139	The potential role of cardiac resynchronization therapy in acute heart failure syndromes. Heart Failure Reviews, 2011, 16, 481-490.	3.9	10
140	Optimizing fluid management in patients with acute decompensated heart failure (ADHF): the emerging role of combined measurement of body hydration status and brain natriuretic peptide (BNP) levels. Heart Failure Reviews, 2011, 16, 519-529.	3.9	95
141	Changes in autonomic balance in patients with decompensated chronic heart failure. Clinical Autonomic Research, 2011, 21, 47-54.	2.5	27
142	Recent Advances in Cardiac Resynchronization Therapy. Postgraduate Medicine, 2011, 123, 18-26.	2.0	5
143	Rationale and design of the multicentre, randomized, doubleâ€blind, placeboâ€controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). European Journal of Heart Failure, 2011, 13, 100-106.	7.1	68
144	Epidemiology and clinical course of heart failure with preserved ejection fraction. European Journal of Heart Failure, 2011, 13, 18-28.	7.1	569
145	Characterization of heart failure patients with preserved ejection fraction: a comparison between ADHERE-US registry and ADHERE-International registry. European Journal of Heart Failure, 2011, 13, 945-952.	7.1	60
146	Factors Associated With Outcome in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2011, 4, 27-35.	3.9	216
147	A large Venous-Arterial PCO2Is Associated with Poor Outcomes in Surgical Patients. Anesthesiology Research and Practice, 2011, 2011, 1-8.	0.7	10
148	Diastolic and Systolic Heart Failure Are Distinct Phenotypes Within the Heart Failure Spectrum. Circulation, 2011, 123, 2006-2014.	1.6	364
149	Clinical assessment of acute heart failure syndromes: emergency department through the early post-discharge period. Heart, 2011, 97, 1607-1618.	2.9	22
150	Meta-Analysis of Renin-Angiotensin-Aldosterone Blockade for Heart Failure in Presence of Preserved Left Ventricular Function. Journal of Cardiovascular Pharmacology and Therapeutics, 2011, 16, 368-375.	2.0	21
151	Cardiorenal Syndrome Caused by Heart Failure with Preserved Ejection Fraction. International Journal of Nephrology, 2011, 2011, 1-7.	1.3	31
152	Chronic Heart Failure: We Are Fighting the Battle, but Are We Winning the War?. Scientifica, 2012, 2012, 1-16.	1.7	7

#	Article	IF	Citations
153	Heart rate variability in patients hospitalized for decompensated diastolic heart failure at admission and after clinical stabilization. Future Cardiology, 2012, 8, 473-482.	1.2	3
154	Angiotensin receptor blockers and outcomes in real-world older patients with heart failure and preserved ejection fraction: a propensity-matched inception cohort clinical effectiveness study. European Journal of Heart Failure, 2012, 14, 1179-1188.	7.1	41
155	The COACH risk engine: a multistate model for predicting survival and hospitalization in patients with heart failure. European Journal of Heart Failure, 2012, 14, 168-175.	7.1	42
156	Communication with hospitalized heart failure patients. European Journal of Cardiovascular Nursing, 2012, 11, 216-222.	0.9	12
158	Care and Outcomes of Hispanic Patients Admitted With Heart Failure With Preserved or Reduced Ejection Fraction. Circulation: Heart Failure, 2012, 5, 167-175.	3.9	48
159	Lifetime Analysis of Hospitalizations and Survival of Patients Newly Admitted With Heart Failure. Circulation: Heart Failure, 2012, 5, 414-421.	3.9	239
160	The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. European Heart Journal, 2012, 33, 1750-1757.	2.2	652
161	Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. Journal of Cardiovascular Medicine, 2012, 13, 415-422.	1.5	29
162	Hemodynamic Classifications of Acute Heart Failure and Their Clinical Application - An Update -. Circulation Journal, 2012, 76, 278-286.	1.6	30
163	Treatment Performance Measures Affect Clinical Outcomes in Patients With Acute Systolic Heart Failure. Circulation Journal, 2012, 76, 1151-1158.	1.6	53
164	Mode of Death in Patients With Heart Failure and Reduced vs. Preserved Ejection Fraction. Circulation Journal, 2012, 76, 1662-1669.	1.6	78
165	Acute Decompensated Heart Failure. Circulation Journal, 2012, 76, 532-543.	1.6	41
166	Pulmonary hypertension and right ventricular dysfunction in left heart disease (group 2 pulmonary) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	3.1	17
167	Pathophysiology of Lower Extremity Edema in Acute Heart Failure Revisited. American Journal of Medicine, 2012, 125, 1124.e1-1124.e8.	1.5	27
168	Molecular and Cellular Basis for Diastolic Dysfunction. Current Heart Failure Reports, 2012, 9, 293-302.	3.3	96
169	What Have We Learned About Patients With Heart Failure and Preserved Ejection Fraction From DIG-PEF, CHARM-Preserved, and I-PRESERVE?. Journal of the American College of Cardiology, 2012, 60, 2349-2356.	2.8	157
170	The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet, The, 2012, 380, 1387-1395.	13.7	990
171	Differences in Outcome of Heart Failure With Preserved or Depressed Systolic Function in Patients Older Than 70 Years Who Receive Beta Blockers. Revista Espanola De Cardiologia (English Ed), 2012, 65, 22-28.	0.6	1

#	Article	IF	Citations
172	Prognosis for Patients With Heart Failure With Preserved Ejection Fraction. Revista Espanola De Cardiologia (English Ed), 2012, 65, 300-301.	0.6	0
173	Trends in Patients Hospitalized With Heart Failure and Preserved Left Ventricular Ejection Fraction. Circulation, 2012, 126, 65-75.	1.6	681
174	Diferencias en el pronÃ³stico de la insuficiencia cardiaca con funciÃ³n sistÃ³lica conservada o deprimida en pacientes mayores de 70 aÃ±os que toman bloqueadores beta. Revista Espanola De Cardiologia, 2012, 65, 22-28.	1.2	3
175	PronÃ³stico de los pacientes con insuficiencia cardiaca y fracciÃ³n de eyecciÃ³n preservada. Revista Espanola De Cardiologia, 2012, 65, 300-301.	1.2	0
176	Design and Performance of a Multisensor Heart Failure Monitoring Algorithm: Results From the Multisensor Monitoring in Congestive Heart Failure (MUSIC) Study. Journal of Cardiac Failure, 2012, 18, 289-295.	1.7	57
177	Predictive Value of Low Relative Lymphocyte Count in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2012, 5, 750-758.	3.9	89
178	Heart Failure in Hypertension. Drugs, 2012, 72, 1373-1398.	10.9	16
179	Is heart failure guideline adherence being underestimated? The impact of therapeutic contraindications. American Heart Journal, 2012, 164, 750-755.e1.	2.7	17
180	Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction. American Heart Journal, 2012, 164, 763-770.e3.	2.7	95
181	Left Atrial Function Predicts Heart Failure Hospitalization in Subjects With Preserved Ejection Fraction and Coronary Heart Disease. Journal of the American College of Cardiology, 2012, 59, 673-680.	2.8	125
182	Impact of Noncardiac Comorbidities on Morbidity and Mortality in a Predominantly Male Population With Heart Failure and Preserved Versus Reduced Ejection Fraction. Journal of the American College of Cardiology, 2012, 59, 998-1005.	2.8	578
183	Association of Arterial Stiffness and Electrocardiography-Determined Left Ventricular Hypertrophy with Left Ventricular Diastolic Dysfunction. PLoS ONE, 2012, 7, e49100.	2.5	18
184	Congestion Is the Driving Force Behind Heart Failure. Current Heart Failure Reports, 2012, 9, 219-227.	3.3	5
185	Trends In Heart Failure Hospitalizations. Current Heart Failure Reports, 2012, 9, 346-353.	3.3	26
186	Expanding Indications for Resynchronization Therapy. Current Cardiology Reports, 2012, 14, 540-546.	2.9	3
187	Cardio-Renal Syndrome Type 1: Epidemiology, Pathophysiology, and Treatment. Seminars in Nephrology, 2012, 32, 18-25.	1.6	39
188	Co-existing disease in vascular surgery patients. , 0, , 22-31.		0
189	Dissecting the â€œCHF admissionâ€• An evidenceâ€based review of the evaluation and management of acute decompensated heart failure for the hospitalist. Journal of Hospital Medicine, 2012, 7, 439-445.	1.4	2

#	Article	IF	Citations
190	Cardio-renal syndromes: a systematic approach for consensus definition and classification. Heart Failure Reviews, 2012, 17, 151-160.	3.9	45
191	Advanced glycation end-products, a pathophysiological pathway in the cardiorenal syndrome. Heart Failure Reviews, 2012, 17, 221-228.	3.9	38
192	A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90Âdays: analysis from the EVEREST trial. Heart Failure Reviews, 2012, 17, 485-509.	3.9	100
193	Association of Serum Triiodothyronine With B-Type Natriuretic Peptide and Severe Left Ventricular Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction. American Journal of Cardiology, 2012, 110, 234-239.	1.6	46
194	Congestive heart failure in the elderly: Comparison between reduced ejection fraction and preserved ejection fraction. Journal of Cardiology, 2012, 59, 215-219.	1.9	14
195	2013 ACCF/AHA Guideline for the Management ofÂHeartÂFailure: Executive Summary. Journal of the American College of Cardiology, 2013, 62, 1495-1539.	2.8	276
196	Heart Failure Readmissions. Current Treatment Options in Cardiovascular Medicine, 2013, 15, 437-449.	0.9	5
197	The Role of the Emergency Department in the Patient with Acute Heart Failure. Current Cardiology Reports, 2013, 15, 365.	2.9	8
198	Acute Heart Failure: Patient Characteristics and Pathophysiology. Current Heart Failure Reports, 2013, 10, 427-433.	3.3	26
199	Acute Heart Failure with Preserved Ejection Fraction: Unique Patient Characteristics and Targets for Therapy. Current Heart Failure Reports, 2013, 10, 190-197.	3.3	22
200	Treatment for chronic heart failure in the elderly: current practice and problems. Heart Failure Reviews, 2013, 18, 529-551.	3.9	73
201	National Patterns of Heart Failure Hospitalizations and Mortality by Sex and Age. Journal of Cardiac Failure, 2013, 19, 542-549.	1.7	27
202	Rehospitalization for Heart Failure. Journal of the American College of Cardiology, 2013, 61, 391-403.	2.8	582
203	Digoxin Reduces 30-day All-cause Hospital Admission in Older Patients with Chronic Systolic Heart Failure. American Journal of Medicine, 2013, 126, 701-708.	1.5	54
204	2013 ACCF/AHA Guideline for the Management of Heart Failure. Circulation, 2013, 128, e240-327.	1.6	2,335
205	Intravenous moderate-dose bumetanide continuous infusion and severe musculoskeletal pain. International Journal of Cardiology, 2013, 168, e29-e31.	1.7	7
206	Update on diastolic heart failure or heart failure with preserved ejection fraction in the older adults. Annals of Medicine, 2013, 45, 37-50.	3.8	56
207	Pulmonary Hypertension, Right Ventricular Function, and Clinical Outcome in Acute Decompensated Heart Failure. Journal of Cardiac Failure, 2013, 19, 665-671.	1.7	70

#	Article	IF	Citations
208	The Emerging Epidemic of Heart Failure with Preserved Ejection Fraction. Current Heart Failure Reports, 2013, 10, 401-410.	3.3	266
209	Prognostic Factors in Patients Hospitalized for Heart Failure. Current Heart Failure Reports, 2013, 10, 380-386.	3.3	7
210	Pathophysiology-based novel pharmacotherapy for heart failure with preserved ejection fraction. , 2013, 140, 156-166.		14
211	Renin-Angiotensin Inhibition in Diastolic Heart Failure and Chronic Kidney Disease. American Journal of Medicine, 2013, 126, 150-161.	1.5	29
212	Update on Heart Failure with Preserved Ejection Fraction. Current Cardiovascular Risk Reports, 2013, 7, 495-502.	2.0	16
213	Progress or lack of progress in hospitalized heart failure. Expert Review of Cardiovascular Therapy, 2013, 11, 1079-1083.	1.5	3
214	Dual neurohormonal intervention in CV disease: angiotensin receptor and Neprilysin inhibition. Expert Opinion on Investigational Drugs, 2013, 22, 915-925.	4.1	23
215	Strategies for Management of Acute Decompensated Heart Failure. , 2013, , 281-306.		0
216	Characterization of acute heart failure hospitalizations in a Portuguese cardiology department. Revista Portuguesa De Cardiologia (English Edition), 2013, 32, 567-575.	0.2	11
217	Design and rationale of studies of neurohormonal blockade and outcomes in diastolic heart failure using OPTIMIZE-HF registry linked to Medicare data. International Journal of Cardiology, 2013, 166, 230-235.	1.7	29
218	Hospitalizations for HeartÂFailure. Heart Failure Clinics, 2013, 9, xi-xii.	2.1	0
219	Clinical characteristics and prognostic influence of renal dysfunction in heart failure patients with preserved ejection fraction. European Journal of Internal Medicine, 2013, 24, 677-683.	2.2	29
220	Profile of the acute heart failure patient in Portugal. Revista Portuguesa De Cardiologia (English) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2	0.2	2
221	Angiotensin-converting Enzyme Inhibitors and Outcomes in Heart Failure and Preserved Ejection Fraction. American Journal of Medicine, 2013, 126, 401-410.	1.5	33
222	Relation between changes in red cell distribution width and clinical outcomes in acute decompensated heart failure. International Journal of Cardiology, 2013, 167, 1412-1416.	1.7	76
223	Return of Digoxin and Recovery of Renal Function. Journal of Cardiac Failure, 2013, 19, 303-305.	1.7	3
224	Strategies to Prevent Postdischarge Adverse Events Among Hospitalized Patients with Heart Failure. Heart Failure Clinics, 2013, 9, 303-320.	2.1	12
225	The Singapore Heart Failure Outcomes and Phenotypes (SHOP) Study and Prospective Evaluation of Outcome in Patients With Heart Failure With Preserved Left Ventricular Ejection Fraction (PEOPLE) Study: Rationale and Design. Journal of Cardiac Failure, 2013, 19, 156-162.	1.7	61

#	Article	IF	Citations
226	Epidemiology of Hospitalized Heart Failure. Heart Failure Clinics, 2013, 9, 271-276.	2.1	13
227	Echocardiographic Left Ventricular End-Diastolic Pressure Volume Loop Estimate Predicts Survival in Congestive Heart Failure. Journal of Cardiac Failure, 2013, 19, 251-259.	1.7	20
228	Myths and Facts About Heart Failure with Preserved Ejection Fraction: Risk Factors, Longevity, Potential Pharmacological and Exercise Interventions. International Journal of Gerontology, 2013, 7, 1-7.	0.6	2
229	Data Sources for Heart Failure Comparative Effectiveness Research. Heart Failure Clinics, 2013, 9, 1-13.	2.1	8
230	Exercise Training in Patients With Heart Failure and Preserved Ejection Fraction. Journal of the American College of Cardiology, 2013, 62, 593-594.	2.8	9
231	Comparison of Medication Practices in Patients With Heart Failure and Preserved Versus Those With Reduced Ejection Fraction (from the Cardiovascular Research Network [CVRN]). American Journal of Cardiology, 2013, 111, 1324-1329.	1.6	17
232	Comparison of Predictors of Heart Failureâ€"Related Hospitalization or Death in Patients With Versus Without Preserved Left Ventricular Ejection Fraction. American Journal of Cardiology, 2013, 112, 1907-1912.	1.6	29
233	Age-Dependent Effect of Left Ventricular Ejection Fraction on Long-Term Mortality in Patients With Heart Failure (from the Heart Failure Survey in ISrael). American Journal of Cardiology, 2013, 112, 1901-1906.	1.6	4
234	Classification of Patients Hospitalized for Heart Failure. Heart Failure Clinics, 2013, 9, 277-283.	2.1	3
235	Drug Therapy to Reduce EarlyÂReadmissionÂRiskÂin Heart Failure. JACC: Heart Failure, 2013, 1, 361-364.	4.1	10
236	Characterization of acute heart failure hospitalizations in a Portuguese cardiology department. Revista Portuguesa De Cardiologia, 2013, 32, 567-575.	0.5	15
237	Profile of the acute heart failure patient in Portugal. Revista Portuguesa De Cardiologia, 2013, 32, 577-579.	0.5	2
238	Is Hospital Admission for Heart Failure Really Necessary?. Journal of the American College of Cardiology, 2013, 61, 121-126.	2.8	120
239	The role of the emergency department in acute heart failure clinical trialsâ€"Enriching patient identification and enrollment. American Heart Journal, 2013, 165, 902-909.	2.7	7
240	Anticoagulation in heart failure: current status and future direction. Heart Failure Reviews, 2013, 18, 797-813.	3.9	28
241	Confounded by Hospitalization: Risk Stratification and Admission Decisions in Emergency Department Patients With Acute Heart Failure. Academic Emergency Medicine, 2013, 20, 106-107.	1.8	4
242	Aldosterone Antagonists and Outcomes in Real-World Older Patients With Heart Failure and Preserved Ejection Fraction. JACC: Heart Failure, 2013, 1, 40-47.	4.1	38
243	Critical reappraisal of pulmonary artery catheterization and invasive hemodynamic assessment in acute heart failure. Expert Review of Cardiovascular Therapy, 2013, 11, 417-424.	1.5	14

#	Article	IF	Citations
244	Specific Etiologies. , 2013, , 199-236.		0
245	2013 ACCF/AHA Guideline for the Management of HeartÂFailure. Journal of the American College of Cardiology, 2013, 62, e147-e239.	2.8	7,017
246	The disconnect between phase II and phase III trials of drugs for heart failure. Nature Reviews Cardiology, 2013, 10, 85-97.	13.7	69
247	Acute Decompensated Heart Failure: Update on New and Emerging Evidence and Directions for Future Research. Journal of Cardiac Failure, 2013, 19, 371-389.	1.7	53
248	Treatment of acute heart failure in the emergency department. Expert Review of Cardiovascular Therapy, 2013, 11, 1195-1209.	1.5	3
249	Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator. European Heart Journal, 2013, 34, 2230-2242.	2.2	104
250	Baseline Characteristics of Patients in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial. Circulation: Heart Failure, 2013, 6, 184-192.	3.9	154
251	Heart Failure With a Normal Left Ventricular Ejection Fraction: Epidemiology Pathophysiology, Diagnosis and Management. American Journal of the Medical Sciences, 2013, 346, 129-136.	1.1	21
252	Timing and Duration of Interventions in Clinical Trials for Patients With Hospitalized Heart Failure. Circulation: Heart Failure, 2013, 6, 1095-1101.	3.9	18
253	2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary. Circulation, 2013, 128, 1810-1852.	1.6	2,807
254	How do patients with heart failure with preserved ejection fraction die?. European Journal of Heart Failure, 2013, 15, 604-613.	7.1	178
255	Effect of oral digoxin in highâ€risk heart failure patients: a preâ€specified subgroup analysis of the DIG trial. European Journal of Heart Failure, 2013, 15, 551-559.	7.1	75
256	Current aspects of the spectrum of acute heart failure syndromes in a realâ€life setting: the OFICA study. European Journal of Heart Failure, 2013, 15, 465-476.	7.1	135
257	Clinical Significance of Abnormal Relaxation Pattern of the Transmitral Flow Velocity Waveform in Older Patients With Preserved Left Ventricular Ejection Fraction. Circulation Journal, 2013, 77, 2551-2557.	1.6	4
258	Epidemiology of Heart Failure in Asia. Circulation Journal, 2013, 77, 2209-2217.	1.6	206
259	Role of Pulsatile Hemodynamics in Acute Heart Failure: Implications for Type 1 Cardiorenal Syndrome. Pulse, 2013, 1, 89-96.	1.9	2
261	Clinical Status and Outcome of Japanese Heart Failure Patients With Reduced or Preserved Ejection Fraction Treated With Carvedilol. International Heart Journal, 2013, 54, 15-22.	1.0	12
264	Acute heart failure: have we got it all wrong?. European Journal of Heart Failure, 2014, 16, 1263-1267.	7.1	2

#	Article	IF	Citations
265	Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. European Heart Journal, 2014, 35, 1041-1050.	2.2	90
266	Breathlessness at rest is not the dominant presentation of patients admitted with heart failure. European Journal of Heart Failure, 2014, 16, 1283-1291.	7.1	51
267	Observational longitudinal cohort study to determine progression to heart failure in a screened community population: the Echocardiographic Heart of England Screening Extension (ECHOES-X) study. BMJ Open, 2014, 4, e005256-e005256.	1.9	5
268	Incident heart failure in relation to vascular disease: Insights from the Health, Aging, and Body Composition Study. European Journal of Heart Failure, 2014, 16, 526-534.	7.1	18
269	Hemoconcentration-guided Diuresis in HeartÂFailure. American Journal of Medicine, 2014, 127, 1154-1159.	1.5	43
270	Noncardiac Comorbidities in HeartÂFailureÂWith Reduced Versus PreservedÂEjection Fraction. Journal of the American College of Cardiology, 2014, 64, 2281-2293.	2.8	424
271	The relationship between left ventricular ejection fraction and mortality in patients with acute heart failure: insights from the <scp>ASCENDâ€HF T</scp>rial. European Journal of Heart Failure, 2014, 16, 334-341.	7.1	56
272	Impaired left atrial function in heart failure with preserved ejection fraction. European Journal of Heart Failure, 2014, 16, 1096-1103.	7.1	194
273	Hospitalized heart failure patients with preserved vs. reduced ejection fraction in Dubai, United Arab Emirates: a prospective study. European Journal of Heart Failure, 2014, 16, 454-460.	7.1	14
274	The middle child in heart failure: heart failure with midâ€range ejection fraction (40â€“50%). European Journal of Heart Failure, 2014, 16, 1049-1055.	7.1	172
275	Heart Failure with Preserved Ejection Fraction. , 2014, , 193-203.		2
276	Hyperglycemia Has a Greater Impact on Left Ventricle Function in South Asians Than in Europeans. Diabetes Care, 2014, 37, 1124-1131.	8.6	18
277	Endpoints for Diuresis. Journal of the American College of Cardiology, 2014, 63, 838-839.	2.8	2
278	Contemporary Profile of Acute Heart Failure inÂSouthern Nigeria. JACC: Heart Failure, 2014, 2, 250-259.	4.1	48
279	Beta-blockers in older patients with heart failure and preserved ejection fraction: Class, dosage, and outcomes. International Journal of Cardiology, 2014, 173, 393-401.	1.7	45
280	Coronary Artery Disease in Patients with Heart Failure: Incidental, Coincidental, or a Target for Therapy?. American Journal of Medicine, 2014, 127, 574-578.	1.5	2
281	Spironolactone for Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine, 2014, 370, 1383-1392.	27.0	1,993
282	The Global Health and Economic Burden ofÂHospitalizations for Heart Failure. Journal of the American College of Cardiology, 2014, 63, 1123-1133.	2.8	1,640

#	Article	IF	Citations
283	Developing Therapies for Heart Failure WithÂPreservedÂEjection Fraction. JACC: Heart Failure, 2014, 2, 97-112.	4.1	267
284	Arterial Hypertension in Patients with Heart Failure. Heart Failure Clinics, 2014, 10, 233-242.	2.1	16
285	Heart failure with preserved ejection fraction: a clinical dilemma. European Heart Journal, 2014, 35, 1022-1032.	2.2	178
286	Comparison of Characteristics and Outcomes of Patients With Heart Failure Preserved Ejection Fraction Versus Reduced Left Ventricular Ejection Fraction in an Urban Cohort. American Journal of Cardiology, 2014, 113, 691-696.	1.6	45
287	Global Perspectives in Hospitalized Heart Failure: Regional and Ethnic Variation in Patient Characteristics, Management, and Outcomes. Current Heart Failure Reports, 2014, 11, 416-427.	3.3	46
288	Epidemiology of Heart Failure with Preserved Ejection Fraction. Heart Failure Clinics, 2014, 10, 377-388.	2.1	86
289	Comorbidities and Differential Diagnosis in Heart Failure with Preserved Ejection Fraction. Heart Failure Clinics, 2014, 10, 481-501.	2.1	33
290	Current Perspectives on Systemic Hypertension in Heart Failure with Preserved Ejection Fraction. Current Cardiology Reports, 2014, 16, 545.	2.9	23
291	Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. American Heart Journal, 2014, 168, 721-730.e3.	2.7	289
292	Prognostic Impact of Combined Late Gadolinium Enhancement on Cardiovascular Magnetic Resonance and Peak Oxygen Consumption in Ambulatory Patients With Nonischemic Dilated Cardiomyopathy. Journal of Cardiac Failure, 2014, 20, 825-832.	1.7	17
293	Calcium Channel Blockers and Outcomes in Older Patients With Heart Failure and Preserved Ejection Fraction. Circulation: Heart Failure, 2014, 7, 945-952.	3.9	32
294	Novel Biomarkers in Heart Failure with Preserved Ejection Fraction. Heart Failure Clinics, 2014, 10, 471-479.	2.1	17
295	Outcomes in Patients with Heart Failure with Preserved Ejection Fraction. Heart Failure Clinics, 2014, 10, 503-510.	2.1	8
296	Can microRNAs emerge as biomarkers in distinguishing HFpEF versus HFrEF?. International Journal of Cardiology, 2014, 175, 395-399.	1.7	23
297	New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. European Heart Journal, 2014, 35, 2797-2815.	2.2	304
298	Diastolic function assessed by cardiac MRI using longitudinal left ventricular fractional shortening. Clinical Imaging, 2014, 38, 666-668.	1.5	14
299	Blood Pressure and Arterial Wall Mechanics in Cardiovascular Diseases. , 2014, , .		20
300	Seeing the Unseen Fibrosis in Heart Failure With Preserved Ejection Fractionâˆ—. JACC: Cardiovascular Imaging, 2014, 7, 998-1000.	5.3	4

#	Article	IF	Citations
301	Potential Roles of Vaptans in Heart Failure. Heart Failure Clinics, 2014, 10, 607-620.	2.1	7
302	Global longitudinal strain in patients with suspected heart failure and a normal ejection fraction: does it improve diagnosis and risk stratification?. International Journal of Cardiovascular Imaging, 2014, 30, 69-79.	1.5	57
303	Influence of Previous Heart Failure Hospitalization on Cardiovascular Events in Patients With Reduced and Preserved Ejection Fraction. Circulation: Heart Failure, 2014, 7, 590-595.	3.9	123
304	Heart Failure With Preserved Ejection Fraction. Circulation Research, 2014, 115, 79-96.	4.5	410
305	Women with Heart Failure: Do They Require a Special Approach for Improving Adherence to Self-Care?. Current Heart Failure Reports, 2014, 11, 307-313.	3.3	5
306	Recombinant Human Relaxin-2: (How) Can a Pregnancy Hormone Save Lives in Acute Heart Failure?. American Journal of Cardiovascular Drugs, 2014, 14, 343-355.	2.2	11
307	Newest additions to heart failure treatment. Expert Opinion on Pharmacotherapy, 2014, 15, 1849-1861.	1.8	1
308	Epidemiology of Heart Failure with Preserved Ejection Fraction. Current Heart Failure Reports, 2014, 11, 354-365.	3.3	91
309	New Insights Into Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction. Seminars in Cardiothoracic and Vascular Anesthesia, 2014, 18, 208-217.	1.0	12
310	Understanding the Epidemic of Heart Failure: Past, Present, and Future. Current Heart Failure Reports, 2014, 11, 404-415.	3.3	157
311	Long-Term Survival for Patients With Acute Decompensated Heart Failure According to Ejection Fraction Findings. American Journal of Cardiology, 2014, 114, 862-868.	1.6	31
312	Digoxin Use and Lower 30-day All-cause Readmission for Medicare Beneficiaries Hospitalized for Heart Failure. American Journal of Medicine, 2014, 127, 61-70.	1.5	50
313	Cardiorenal syndrome. Clinical Queries Nephrology, 2014, 3, 30-37.	0.2	3
314	In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs.) Tj ETQq1 1 0.784314 rgBT /Over Cardiology, 2014, 173, 163-169.	1.7	98
315	Performance Matters in Heart Failure. Journal of the American College of Cardiology, 2014, 63, 131-132.	2.8	2
316	Effects of Spironolactone Treatment in Elderly Women With Heart Failure and Preserved Left Ventricular Ejection Fraction. Journal of Cardiac Failure, 2014, 20, 560-568.	1.7	38
317	Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. Heart Failure Reviews, 2014, 19, 135-152.	3.9	48
318	The Hemodynamic and Nonhemodynamic Crosstalk in Cardiorenal Syndrome Type 1. CardioRenal Medicine, 2014, 4, 103-112.	1.9	33

#	Article	IF	Citations
319	Low Systolic Blood Pressure on Admission Predicts Mortality in Patients With Acute Decompensated Heart Failure Due to Moderate to Severe Aortic Stenosis. Circulation Journal, 2014, 78, 2455-2459.	1.6	9
320	Treatment of Heart Failure in Realâ€World Clinical Practice: Findings From the <scp>REFLECTâ€HF</scp> Registry in Patients With <scp>NYHA</scp> Class <scp>II</scp> Symptoms and a Reduced Ejection Fraction. Clinical Cardiology, 2015, 38, 200-207.	1.8	16
321	Prognostic Impact of Statin Use in Patients With Heart Failure and Preserved Ejection Fraction. Circulation Journal, 2015, 79, 574-582.	1.6	55
322	Noncardiac Comorbidities in Heart Failure With Preserved Ejection Fractionã€€â€“ A Commonly Ignored Fact â€“. Circulation Journal, 2015, 79, 954-959.	1.6	29
323	Current Challenges in the Management of Heart Failure. Circulation Journal, 2015, 79, 948-953.	1.6	25
324	Left Ventricular Ejection Fraction (EF) of 55% as Cutoff for Late Transition From Heart Failure (HF) With Preserved EF to HF With Mildly Reduced EF. Circulation Journal, 2015, 79, 2209-2215.	1.6	35
325	The Optimal Cut-off Value of Plasma BNP to Differentiate Heart Failure in the Emergency Department in Japanese Patients with Dyspnea. Internal Medicine, 2015, 54, 2975-2980.	0.7	9
326	Serum uric acid is associated with cardiac diastolic dysfunction among women with preserved ejection fraction. American Journal of Physiology - Heart and Circulatory Physiology, 2015, 309, H986-H994.	3.2	24
327	Strategies to Reduce Heart Failure Hospitalizations and Readmissions: How Low Can We Go?. Cardiovascular Innovations and Applications, 2015, 1, .	0.3	0
328	Right ventricular systolic dysfunction and its prognostic value in heart failure with preserved ejection fraction. Acta Cardiologica, 2015, 70, 387-393.	0.9	12
329	Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: critical appraisal and practical use. European Journal of Heart Failure, 2015, 17, 1231-1239.	7.1	85
330	Obesity Paradox: Origin and best way to assess severity in patients with systolic HF. Obesity, 2015, 23, 2002-2008.	3.0	14
331	Heart Failure With Preserved Ejection Fraction. Cardiology in Review, 2015, 23, 161-167.	1.4	10
332	Outcomes of heart failure with preserved ejection fraction in a Southeast Asian cohort. Journal of Cardiovascular Medicine, 2015, 16, 583-590.	1.5	7
333	Position paper FADOI sulla prevenzione cardiovascolare nei pazienti complessi a rischio. Italian Journal of Medicine, 2015, 3, 309.	0.3	1
334	Causes and predictors of hospital readmissions in patients older than 65 years hospitalized for heart failure with preserved left ventricular ejection fraction in western Romania. Clinical Interventions in Aging, 2015, 10, 979.	2.9	9
335	Sustained Toll-Like Receptor 9 Activation Promotes Systemic and Cardiac Inflammation, and Aggravates Diastolic Heart Failure in SERCA2a KO Mice. PLoS ONE, 2015, 10, e0139715.	2.5	13
336	Vasopressin V₂ Receptor Antagonist Tolvaptan Is Effective in Heart Failure Patients With Reduced Left Ventricular Systolic Function and Low Blood Pressure. International Heart Journal, 2015, 56, 213-218.	1.0	18

#	Article	IF	Citations
337	Challenging aspects of treatment strategies in heart failure with preserved ejection fraction: â€œWhy did recent clinical trials fail?â€•. World Journal of Cardiology, 2015, 7, 544.	1.5	15
338	Effect of Inorganic Nitrate on Exercise Capacity in Heart Failure With Preserved Ejection Fraction. Circulation, 2015, 131, 371-380.	1.6	251
339	A Contemporary Appraisal of the Heart Failure Epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Internal Medicine, 2015, 175, 996.	5.1	581
340	Characterization of diastolic dysfunction heart failure following an acute hospitalization for heart failure in an urban, underserved population. Therapeutic Advances in Cardiovascular Disease, 2015, 9, 267-274.	2.1	0
341	Congestive Heart Failure With Apparently Preserved Left Ventricular Systolic Function. Angiology, 2015, 66, 738-744.	1.8	1
342	2015 Guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the Management of Hypertension. Journal of the Chinese Medical Association, 2015, 78, 1-47.	1.4	183
343	Utility of Peak Creatine Kinase-MB Measurements in Predicting Myocardial Infarct Size, Left Ventricular Dysfunction, and Outcome After First Anterior Wall Acute Myocardial Infarction (from) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	1.6	67
344	Predictors of two-year mortality in Asian patients with heart failure and preserved ejection fraction. International Journal of Cardiology, 2015, 183, 33-38.	1.7	27
345	Loop diuretic dose adjustments after a hospitalization for heart failure: insights from <scp>ASCENDâ€HF</scp>. European Journal of Heart Failure, 2015, 17, 340-346.	7.1	22
346	Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. European Heart Journal, 2015, 36, 915-923.	2.2	51
347	Relation of Left Ventricular Ejection Fraction and Clinical Features or Co-morbidities to Outcomes Among Patients Hospitalized for Acute Heart Failure Syndromes. American Journal of Cardiology, 2015, 115, 334-340.	1.6	16
348	Acute Heart Failure: Epidemiology, Risk Factors, and Prevention. Revista Espanola De Cardiologia (English Ed), 2015, 68, 245-248.	0.6	64
350	SGLT-2 Inhibitors: Potential Novel Strategy to Prevent Congestive Heart Failure in Diabetes?. Current Cardiovascular Risk Reports, 2015, 9, 1.	2.0	7
351	Association Between Use of Statins and Mortality in Patients With Heart Failure and Ejection Fraction of â‰¥50%. Circulation: Heart Failure, 2015, 8, 862-870.	3.9	83
352	Non-cardiovascular comorbidity, severity and prognosis in non-selected heart failure populations: A systematic review and meta-analysis. International Journal of Cardiology, 2015, 196, 98-106.	1.7	57
353	Acute Effects of Biventricular Pacing in Heart Failure Patients with a Normal Ejection Fraction and Mechanical Dyssynchrony. Cardiology, 2015, 130, 112-119.	1.4	2
354	Heart Failure with Preserved Ejection Fraction. Hospital Medicine Clinics, 2015, 4, 283-296.	0.2	0
355	Longitudinal Strain in Heart Failure With Preserved Ejection Fraction. Circulation, 2015, 132, 368-370.	1.6	13

#	Article	IF	Citations
356	Heart failure with preserved ejection fraction in the elderly: scope of the problem. Journal of Molecular and Cellular Cardiology, 2015, 83, 73-87.	1.9	113
357	Prognostic scores in heart failure â€" Critical appraisal and practical use. International Journal of Cardiology, 2015, 188, 1-9.	1.7	45
358	Clinical outcome of transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel implant. International Journal of Cardiology, 2015, 187, 227-228.	1.7	30
359	The Potential Role of Natriuretic Peptideâ€"Guided Management for Patients Hospitalized for Heart Failure. Journal of Cardiac Failure, 2015, 21, 233-239.	1.7	16
360	Impact on mortality of systolic and/or diastolic heart failure in the elderlyâ€"10Âyears of follow-up. Journal of Clinical Gerontology and Geriatrics, 2015, 6, 20-26.	0.7	1
361	Patient Selection in Heart Failure With Preserved Ejection Fraction Clinical Trials. Journal of the American College of Cardiology, 2015, 65, 1668-1682.	2.8	116
362	Effects of mineralocorticoid receptor antagonists in patients with preserved ejection fraction: a meta-analysis of randomized clinical trials. BMC Medicine, 2015, 13, 10.	5.5	27
363	The Hospitalization Burden and Post-Hospitalization Mortality Risk in HeartÂFailure With Preserved EjectionÂFraction. JACC: Heart Failure, 2015, 3, 429-441.	4.1	72
364	Medical Treatment of Heart Failure and Coronary Heart Disease. Cardiovascular Medicine, 2015, , 533-560.	0.0	0
365	Update on management of heart failure with preserved ejection fraction. Current Opinion in Cardiology, 2015, 30, 173-178.	1.8	6
366	Soothing the sleeping giant: improving skeletal muscle oxygen kinetics and exercise intolerance in HFpEF. Journal of Applied Physiology, 2015, 119, 734-738.	2.5	21
367	Current Approach to Decongestive Therapy in Acute Heart Failure. Current Heart Failure Reports, 2015, 12, 367-378.	3.3	39
368	Heart failure with preserved ejection fraction: uncertainties and dilemmas. European Journal of Heart Failure, 2015, 17, 665-671.	7.1	124
369	Spironolactone for Management of Heart Failure with Preserved Ejection Fraction: Whither to After TOPCAT?. Current Atherosclerosis Reports, 2015, 17, 64.	4.8	15
370	Identification of Emergency Department Patients With Acute Heart Failure at LowÂRisk for 30-Day Adverse Events. JACC: Heart Failure, 2015, 3, 737-747.	4.1	83
371	Overview of Heart Failure in Argentina. , 2015, , 287-304.		1
372	In-hospital management of acute heart failure: Practical recommendations and future perspectives. International Journal of Cardiology, 2015, 201, 231-236.	1.7	31
373	Outcomes and Worsening Renal Function in Patients Hospitalized With Heart Failure With Preserved Ejection Fraction. American Journal of Cardiology, 2015, 116, 1534-1540.	1.6	26

#	Article	IF	Citations
374	Discharge Hospice Referral and Lower 30-Day All-Cause Readmission in Medicare Beneficiaries Hospitalized for Heart Failure. Circulation: Heart Failure, 2015, 8, 733-740.	3.9	30
376	Risk Adjusted Mortality Ratings and Public Reporting for High-Risk PCI. JACC: Cardiovascular Interventions, 2015, 8, 1134-1135.	2.9	3
377	Early Management of Patients With Acute Heart Failure: State of the Art and Future Directionsâ€"A Consensus Document from the <scp>SAEM</scp>/<scp>HFSA</scp> Acute Heart Failure Working Group. Academic Emergency Medicine, 2015, 22, 94-112.	1.8	41
378	Speckle Strain Echocardiography Predicts Outcome in Patients with Heart Failure with both Depressed and Preserved Left Ventricular Ejection Fraction. Echocardiography, 2015, 32, 71-78.	0.9	58
379	Early Management of Patients With Acute Heart Failure: State of the Art and Future Directions. A Consensus Document From the Society for Academic Emergency Medicine/Heart Failure Society of America Acute Heart Failure Working Group. Journal of Cardiac Failure, 2015, 21, 27-43.	1.7	73
380	Beta-blockers in heart failure with preserved ejection fraction: a meta-analysis. Heart Failure Reviews, 2015, 20, 193-201.	3.9	86
381	CARDIORENAL INTERACTION IN DECOMPENSATED CHRONIC HEART FAILURE. Rational Pharmacotherapy in Cardiology, 2016, 12, 138-146.	0.8	8
382	Prognostic value of echocardiography and ECG in heart failure with preserved ejection fraction. Bratislava Medical Journal, 2016, 117, 407-412.	0.8	3
383	Patterns of scheduled follow-up appointments following hospitalization for heart failure: insights from an urban medical center in the United States. Clinical Interventions in Aging, 2016, Volume 11, 1325-1332.	2.9	9
384	Prevalence and Risk Factors of Heart Failure with Preserved Ejection Fraction: A Population-Based Study in Northeast China. International Journal of Environmental Research and Public Health, 2016, 13, 770.	2.6	23
385	The Pathophysiology of Heart Failure in Children: The Basics. Current Cardiology Reviews, 2016, 12, 99-103.	1.5	9
386	Use of Lung Ultrasound For Diagnosing Acute Heart Failure in Emergency Department of Southern India. Journal of Clinical and Diagnostic Research JCDR, 2016, 10, TC05-TC08.	0.8	7
387	Heart failure with multiple comorbidities. Current Opinion in Cardiology, 2016, 31, 209-216.	1.8	17
388	Diagnosis, Clinical Course, and 1-Year Outcome in Patients Hospitalized for Heart Failure With Preserved Ejection Fraction (from the Polish Cohort of the European Society of Cardiology Heart) Tj ETQq1 1 0.784314 rgBT /Overlock	3.4	10
389	Left ventricular diastolic dysfunction and increased left ventricular mass index related to pulmonary hypertension in patients with systemic autoimmune disease without pericardial effusion. International Journal of Cardiology, 2016, 220, 268-272.	1.7	5
390	Reporting trends of randomised controlled trials in heart failure with preserved ejection fraction: a systematic review. Open Heart, 2016, 3, e000449.	2.3	14
391	Heart failure epidemiology and novel treatments in Japan: facts and numbers. ESC Heart Failure, 2016, 3, 145-151.	3.1	82
392	The Three-Decade Long Journey in Heart Failure Drug Development. Handbook of Experimental Pharmacology, 2016, 243, 1-14.	1.8	12

#	Article	IF	Citations
393	The clinical dilemma of heart failure with preserved ejection fraction: an update on pathophysiology and management for physicians. Postgraduate Medical Journal, 2016, 92, 346-355.	1.8	6
394	IMproved exercise tolerance in patients with PReserved Ejection fraction by Spironolactone on myocardial fibrosiS in Atrial Fibrillation rationale and design of the IMPRESS-AF randomised controlled trial. BMJ Open, 2016, 6, e012241.	1.9	14
395	Understanding heart failure with preserved ejection fraction: where are we today?. Netherlands Heart Journal, 2016, 24, 227-236.	0.8	71
396	Sex Differences in the Management and Outcomes of Heart Failure With Preserved Ejection Fraction in Patients Presenting to the Emergency Department With Acute Heart Failure. Journal of Cardiac Failure, 2016, 22, 781-788.	1.7	24
397	Toward Sex-Specific Guidelines for Cardiac Resynchronization Therapy?. Journal of Cardiovascular Translational Research, 2016, 9, 12-22.	2.4	13
398	Accuracy of bioimpedance vector analysis and brain natriuretic peptide in detection of peripheral edema in acute and chronic heart failure. Heart and Lung: Journal of Acute and Critical Care, 2016, 45, 319-326.	1.6	47
399	An effect of left ventricular hypertrophy on mild-to-moderate left ventricular diastolic dysfunction. Hellenic Journal of Cardiology, 2016, 57, 92-98.	1.0	22
400	Characteristics of Hospitalizations for Heart Failure with Preserved Ejection Fraction. American Journal of Medicine, 2016, 129, 635.e15-635.e26.	1.5	90
401	Discordance Between Hemoconcentration and Clinical Assessment of Decongestion in Acute Heart Failure. Journal of Cardiac Failure, 2016, 22, 680-688.	1.7	23
402	Heart Failure After CABG. , 2016, , 189-197.		0
403	Heart Failure and Midrange Ejection Fraction. Circulation: Heart Failure, 2016, 9, e002826.	3.9	84
404	Etiology of Heart Failure and Outcomes in Patients Hospitalized for Acute Decompensated Heart Failure With Preserved or Reduced Ejection Fraction. American Journal of Cardiology, 2016, 118, 1881-1887.	1.6	13
405	A tentative interpretation of the <scp>TOPCAT</scp> trial based on randomized evidence from the brain natriuretic peptide stratum analysis. European Journal of Heart Failure, 2016, 18, 1411-1414.	7.1	31
406	Reframing the association and significance of coâ€morbidities in heart failure. European Journal of Heart Failure, 2016, 18, 744-758.	7.1	169
407	Regional and ethnic differences among patients with heart failure in Asia: the Asian sudden cardiac death in heart failure registry. European Heart Journal, 2016, 37, 3141-3153.	2.2	144
408	Red cell distribution width and mortality in acute heart failure patients with preserved and reduced ejection fraction. ESC Heart Failure, 2016, 3, 198-204.	3.1	51
409	Heart failure with normal ejection fraction is uncommon in acute myocardial infarction settings but associated with poor outcomes: a study of 91 360 patients admitted with index myocardial infarction between 1998 and 2010. European Journal of Heart Failure, 2016, 18, 46-53.	7.1	19
410	Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review. European Journal of Heart Failure, 2016, 18, 54-65.	7.1	73

#	Article	IF	Citations
411	Incidence and risk factors for thromboembolism and major bleeding in patients with mechanical valve prosthesis: A nationwide population-based study. American Heart Journal, 2016, 181, 1-9.	2.7	24
412	Relation Between Echocardiogram-Based Cardiac Parameters and Outcome in Heart Failure With Preserved and Reduced Ejection Fraction. American Journal of Cardiology, 2016, 118, 1356-1362.	1.6	20
413	Patients with HFpEF and HFrEF have different clinical characteristics but similar prognosis: a retrospective cohort study. BMC Cardiovascular Disorders, 2016, 16, 232.	1.7	67
414	Nâ€terminal proâ€brain natriuretic peptide is a useful marker to identify latent heart failure patients in older adults in a rural outpatient clinic. Geriatrics and Gerontology International, 2017, 17, 1648-1653.	1.5	1
415	Relationship of Left Ventricular Diastolic Function to Obesity and Overweight in a Japanese Population With Preserved Left Ventricular Ejection Fraction. Circulation Journal, 2016, 80, 1951-1956.	1.6	17
416	Transtubular Potassium Concentration Gradient as a Surrogate Measure of Arterial Underfilling in Acute Decompensated Heart Failure. Circulation Journal, 2016, 80, 1965-1970.	1.6	1
417	Development of Therapeutics for Heart Failure. Circulation: Heart Failure, 2016, 9, .	3.9	0
418	Differential Response to Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Reduced or Preserved Ejection Fraction. Circulation: Heart Failure, 2016, 9, .	3.9	46
419	Comparison of Characteristics and Outcomes of Heart Failure Patients With Preserved Versus Reduced Ejection Fraction in a Multiethnic Southeast Asian Cohort. American Journal of Cardiology, 2016, 118, 1233-1238.	1.6	12
420	Pulmonary Hypertension in Patients with Heart Failure and Preserved Ejection Fraction: Differential Diagnosis and Management. Pulmonary Circulation, 2016, 6, 3-14.	1.7	20
421	Heart Failure With Preserved EjectionÂFraction andÂAtrial Fibrillation. Journal of the American College of Cardiology, 2016, 68, 2217-2228.	2.8	292
422	Myocardial reverse remodeling: how far can we rewind?. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 310, H1402-H1422.	3.2	32
423	Factors related to outcome in heart failure with a preserved (or normal) left ventricular ejection fraction. European Heart Journal Quality of Care & Clinical Outcomes, 2016, 2, 153-163.	4.0	9
424	Predicting Heart Failure Readmissions. Journal of Cardiovascular Nursing, 2016, 31, 114-120.	1.1	10
425	Does Treating Sleep Apnea Reduce Heart Failure Risks?. Current Cardiovascular Risk Reports, 2016, 10, 1.	2.0	0
427	Is the diagnostic coding position of acute heart failure related to mortality? A report from the Euro Heart Failure Surveyâ€1. European Journal of Heart Failure, 2016, 18, 556-563.	7.1	8
428	A Critical Evaluation of the Representation of Black Patients With Heart Failure and Preserved Ejection Fraction in Clinical Trials. Journal of Cardiovascular Nursing, 2016, 31, 202-208.	1.1	2
429	Clinical Characteristics, Management, and Outcomes of Hospitalized Heart Failure in a Chinese Populationâ€"The Hong Kong Heart Failure Registry. Journal of Cardiac Failure, 2016, 22, 600-608.	1.7	38

#	Article	IF	Citations
430	Combining angiotensin II receptor 1 antagonism and neprilysin inhibition for the treatment of heart failure. Expert Review of Clinical Pharmacology, 2016, 9, 513-523.	3.1	7
431	Cost-Effectiveness of Implantable Pulmonary Artery Pressure Monitoring inÂChronic Heart Failure. JACC: Heart Failure, 2016, 4, 368-375.	4.1	74
432	The Nitrate-Nitrite-NO Pathway and Its Implications for Heart Failure and Preserved Ejection Fraction. Current Heart Failure Reports, 2016, 13, 47-59.	3.3	52
433	Heart Failure With Preserved Ejection Fraction. Current Problems in Cardiology, 2016, 41, 145-188.	2.4	107
434	Current treatment approaches and trials in central sleep apnea. International Journal of Cardiology, 2016, 206, S22-S27.	1.7	10
435	Monocyte Subsets and Inflammatory Cytokines in Acute Decompensated Heart Failure. Journal of Cardiac Failure, 2016, 22, 358-365.	1.7	26
436	From comorbidities to heart failure with preserved ejection fraction: a story of oxidative stress. Heart, 2016, 102, 320-330.	2.9	29
437	Relaxinâ€™ the Heart. Journal of Cardiovascular Pharmacology and Therapeutics, 2016, 21, 353-362.	2.0	22
438	Survivors of acute myocardial infarction at left main trunk undergoing primary percutaneous coronary intervention. Cardiovascular Intervention and Therapeutics, 2016, 31, 89-95.	2.3	7
439	Editorâ€™s Choice- Call to action: Initiation of multidisciplinary care for acute heart failure begins in the Emergency Department. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 141-149.	1.0	14
440	Patients with left ventricular ejection fraction greater than 58Â% have fewer incidences of future acute decompensated heart failure admission and all-cause mortality. Heart and Vessels, 2016, 31, 734-743.	1.2	19
441	Role of Neprilysin Inhibitors in Heart Failure. American Journal of Therapeutics, 2017, 24, e737-e743.	0.9	4
442	Carga de hospitalizaciones recurrentes tras unaÂhospitalizaciÃ³n porÂinsuficiencia cardiaca aguda: insuficiencia cardiaca con funciÃ³n sistÃ³lica conservada frente a reducida. Revista Espanola De Cardiologia, 2017, 70, 239-246.	1.2	66
443	La fracciÃ³n de eyecciÃ³n intermedia no permite estratificar el riesgo de los pacientes hospitalizados por insuficiencia cardiaca. Revista Espanola De Cardiologia, 2017, 70, 338-346.	1.2	47
444	Short Stay Management of Acute Heart Failure. Contemporary Cardiology, 2017, , .	0.1	0
445	Pharmacological reasons that may explain why randomized clinical trials have failed in acute heart failure syndromes. International Journal of Cardiology, 2017, 233, 1-11.	1.7	8
446	The association of chronic kidney disease and microalbuminuria with heart failure with preserved vs. reduced ejection fraction. European Journal of Heart Failure, 2017, 19, 615-623.	7.1	44
447	Heart failure drug changes the mechanoenzymology of the cardiac myosin powerstroke. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E1796-E1804.	7.1	76

#	Article	IF	Citations
448	Isosorbide Dinitrate, With or Without Hydralazine, Does Not Reduce Wave Reflections, Left Ventricular Hypertrophy, or Myocardial Fibrosis in Patients With Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2017, 6, .	3.7	36
450	Current Perspectives on Systemic Hypertension in Heart Failure with Preserved Ejection Fraction. Current Hypertension Reports, 2017, 19, 12.	3.5	38
451	Burden and Timing of Hospitalizations in Heart Failure: A Community Study. Mayo Clinic Proceedings, 2017, 92, 184-192.	3.0	42
452	Heart Failure Incidence and Mortality in the Southern Community Cohort Study. Circulation: Heart Failure, 2017, 10, .	3.9	24
453	Towards Precision in HF Pharmacotherapy. Current Heart Failure Reports, 2017, 14, 1-6.	3.3	3
454	Entresto (Sacubitril/Valsartan): Angiotensin Receptor Neprilysin Inhibition for Treating Heart Failure. Current Emergency and Hospital Medicine Reports, 2017, 5, 47-55.	1.5	0
455	Is there a clinically meaningful difference in patient reported dyspnea in acute heart failure? An analysis from URGENT Dyspnea. Heart and Lung: Journal of Acute and Critical Care, 2017, 46, 300-307.	1.6	12
456	Addressing the Heterogeneity of Heart Failure in Future Randomized Trials. Current Heart Failure Reports, 2017, 14, 197-202.	3.3	17
457	Trajectory of Congestion Metrics by Ejection Fraction inÂPatients With Acute Heart Failure (from the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.6	15
458	Epidemiology of heart failure with preserved ejection fraction. Nature Reviews Cardiology, 2017, 14, 591-602.	13.7	902
459	Aortic stiffening precedes onset of heart failure with preserved ejection fraction in patients with asymptomatic diastolic dysfunction. BMC Cardiovascular Disorders, 2017, 17, 62.	1.7	23
460	Prevalence and correlates of left ventricular diastolic dysfunction and heart failure with preserved ejection fraction in elderly community residents. International Journal of Cardiology, 2017, 227, 820-825.	1.7	6
461	The Syndrome of Heart Failure With Preserved Systolic Function. Revista Espanola De Cardiologia (English Ed), 2017, 70, 232-233.	0.6	1
462	Cardiac T1 Mapping and Extracellular Volume (ECV) in clinical practice: a comprehensive review. Journal of Cardiovascular Magnetic Resonance, 2017, 18, 89.	3.3	551
463	Race/Ethnic Differences in Outcomes Among Hospitalized Medicare Patients With Heart Failure and Preserved EjectionÂFraction. JACC: Heart Failure, 2017, 5, 483-493.	4.1	41
464	Impact of a Pharmacist-Managed Heart Failure Postdischarge (Bridge) Clinic for Veterans. Annals of Pharmacotherapy, 2017, 51, 555-562.	1.9	31
465	Etiologies, Trends, and Predictors of 30-Day Readmissions in Patients With Diastolic Heart Failure. American Journal of Cardiology, 2017, 120, 616-624.	1.6	35
466	Comparison of central and peripheral hemodynamics in association with left ventricular diastolic dysfunction in the community-based elderly Chinese. Journal of the American Society of Hypertension, 2017, 11, 366-375.	2.3	2

#	Article	IF	Citations
467	Epidemiology, Pathophysiology, and Prognosis of Heart Failure in Older Adults. Heart Failure Clinics, 2017, 13, 417-426.	2.1	166
468	Heart Failure with Preserved Ejection Fraction in Older Adults. Heart Failure Clinics, 2017, 13, 485-502.	2.1	50
469	Comparison of Predictors of Heart Failure With Preserved Versus Reduced Ejection Fraction in a Multiracial Cohort of Preclinical Left Ventricular Diastolic Dysfunction. American Journal of Cardiology, 2017, 119, 1815-1820.	1.6	20
470	Prognostic Factors After Index Hospitalization for Heart Failure With Preserved Ejection Fraction. American Journal of Cardiology, 2017, 119, 2017-2020.	1.6	29
471	Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. European Heart Journal, 2017, 38, 1119-1127.	2.2	285
472	Management of Heart Failure with Preserved Ejection Fraction: Current Challenges and Future Directions. American Journal of Cardiovascular Drugs, 2017, 17, 283-298.	2.2	10
473	Epidemiology and oneâ€year outcomes in patients with chronic heart failure and preserved, midâ€range and reduced ejection fraction: an analysis of the ESC Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2017, 19, 1574-1585.	7.1	568
474	Sexâ€and Raceâ€Related Differences in Characteristics and Outcomes of Hospitalizations for Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2017, 6, .	3.7	36
475	Heart failure with midâ€range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (<scp>TIMEâ€CHF</scp>). European Journal of Heart Failure, 2017, 19, 1586-1596.	7.1	108
476	Promise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond. Current Treatment Options in Cardiovascular Medicine, 2017, 19, 23.	0.9	69
477	Sitagliptin reduces inflammation, fibrosis and preserves diastolic function in a rat model of heart failure with preserved ejection fraction. British Journal of Pharmacology, 2017, 174, 4070-4086.	5.4	58
478	Acute heart failure with mid-range left ventricular ejection fraction: clinical profile, in-hospital management, and short-term outcome. Clinical Research in Cardiology, 2017, 106, 359-368.	3.3	57
479	Association of New York Heart Association functional class IV symptoms at admission and clinical features with outcomes in patients hospitalized for acute heart failure syndromes. International Journal of Cardiology, 2017, 230, 585-591.	1.7	8
480	Mid-range Ejection Fraction Does Not Permit Risk Stratification Among Patients Hospitalized for Heart Failure. Revista Espanola De Cardiologia (English Ed), 2017, 70, 338-346.	0.6	29
481	Ï‰3-Polyunsaturated fatty acids for heart failure: Effects of dose on efficacy and novel signaling through free fatty acid receptor 4. Journal of Molecular and Cellular Cardiology, 2017, 103, 74-92.	1.9	56
482	Heart Rate and Outcomes in HospitalizedÂPatients With Heart Failure With Preserved EjectionÂFraction. Journal of the American College of Cardiology, 2017, 70, 1861-1871.	2.8	34
483	Pathophysiology of Atrial Fibrillation. Cardiovascular Medicine, 2017, , 15-25.	0.0	1
484	A comprehensive populationâ€based characterization of heart failure with midâ€range ejection fraction. European Journal of Heart Failure, 2017, 19, 1624-1634.	7.1	196

#	Article	IF	Citations
485	Heart Failure With Mid-Range (Borderline) Ejection Fraction. JACC: Heart Failure, 2017, 5, 763-771.	4.1	141
486	Acute heart failure: Epidemiology and socioeconomic burden. Continuing Cardiology Education, 2017, 3, 88-92.	0.4	11
487	Prognostic Significance of Low Systolic Blood Pressure at Discharge in Patients with Heart Failure and Preserved Ejection Fraction. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 405-412.	2.2	0
488	Atrial Fibrillation in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction. JACC: Heart Failure, 2017, 5, 565-574.	4.1	236
489	Evolution of a Geriatric Syndrome: Pathophysiology and Treatment of Heart Failure with Preserved Ejection Fraction. Journal of the American Geriatrics Society, 2017, 65, 2431-2440.	2.6	61
490	Heart rate and outcomes in patients with heart failure with preserved ejection fraction. Medicine (United States), 2017, 96, e8431.	1.0	16
491	Novel Endpoints for Heart Failure Clinical Trials. Current Heart Failure Reports, 2017, 14, 210-216.	3.3	12
492	Angiotensin Receptor Neprilysin InhibitionÂin Heart Failure With PreservedÂEjection Fraction. JACC: Heart Failure, 2017, 5, 471-482.	4.1	238
493	Peripheral Venous Pressure Measurements in Patients With Acute Decompensated Heart Failure (PVP-HF). Circulation: Heart Failure, 2017, 10, .	3.9	16
494	Effect of cardiovascular risk factors and time of hospital presentation on mortality of maintenance hemodialysis patients presenting with acute pulmonary edema. Renal Replacement Therapy, 2017, 3, .	0.7	0
495	Clinical Application of Biomarkers in Heart Failure with a Preserved Ejection Fraction: A Review. Cardiology, 2017, 136, 192-203.	1.4	16
496	Novel Biomarkers of Heart Failure. Advances in Clinical Chemistry, 2017, 79, 93-152.	3.7	93
497	Burden of Recurrent Hospitalizations Following an Admission for Acute Heart Failure: Preserved Versus Reduced Ejection Fraction. Revista Espanola De Cardiologia (English Ed), 2017, 70, 239-246.	0.6	22
498	Application of empirical mode decomposition (EMD) for automated identification of congestive heart failure using heart rate signals. Neural Computing and Applications, 2017, 28, 3073-3094.	5.6	53
499	Deliberations on Diastolic Heart Failure. American Journal of Cardiology, 2017, 119, 138-144.	1.6	9
500	Baseline characteristics of patients with heart failure and preserved ejection fraction at admission with acute heart failure in Saudi Arabia. Egyptian Heart Journal, 2017, 69, 21-28.	1.2	7
501	Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction. Journal of Cardiac Failure, 2017, 23, 20-28.	1.7	35
502	Renal dysfunction and diastolic impairment among British ethnic minorities with hypertension: the Ethnic-Echocardiographic Heart of England Screening Study. Journal of Human Hypertension, 2017, 31, 206-211.	2.2	1

#	Article	IF	Citations
503	Hypertension and Heart Failure with Preserved Ejection Fraction: Connecting the Dots. Current Vascular Pharmacology, 2017, 16, 15-22.	1.7	24
504	Global Public Health Burden of Heart Failure. Cardiac Failure Review, 2017, 03, 7.	3.0	1,731
505	Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives. Vascular Health and Risk Management, 2017, Volume 13, 369-382.	2.3	18
506	Tratamiento farmacolÃ³gico de la insuficiencia cardÃaca. Â¿QuÃ© hay de nuevo?. Revista Uruguaya De CardiologÃa, 2017, 32, .	0.0	1
507	Interatrial shunt devices for heart failure with normal ejection fraction: a technology update. Medical Devices: Evidence and Research, 2017, Volume 10, 123-132.	0.8	2
508	Cardiac troponin and outcome in decompensated heart failure with preserved ejection fraction. Cardiovascular Diagnosis and Therapy, 2017, 7, 359-366.	1.7	14
509	Profile of Patients Hospitalized for Heart Failure in Tertiary Care Hospital. International Journal of Cardiovascular Sciences, 2017, , .	0.1	5
510	Insuficiencia cardÃaca aguda. Revista Uruguaya De CardiologÃa, 2017, 32, .	0.0	2
511	Optimizing Hypertensive Acute Heart Failure Management with Afterload Reduction. Current Hypertension Reports, 2018, 20, 9.	3.5	15
512	Pulmonary hypertension in chronic lung diseases: comparison to other pulmonary hypertension groups. Pulmonary Circulation, 2018, 8, 1-10.	1.7	30
513	Nitrite circumvents platelet resistance to nitric oxide in patients with heart failure preserved ejection fraction and chronic atrial fibrillation. Cardiovascular Research, 2018, 114, 1313-1323.	3.8	12
514	Heart rate response and functional capacity in patients with chronic heart failure with preserved ejection fraction. ESC Heart Failure, 2018, 5, 579-585.	3.1	23
515	Combination of Mean Platelet Volume/Platelet Count Ratio and the APACHE II Score Better Predicts the Short-Term Outcome in Patients with Acute Kidney Injury Receiving Continuous Renal Replacement Therapy. Kidney and Blood Pressure Research, 2018, 43, 479-489.	2.0	13
516	The contribution of comorbidities to mortality in hospitalized patients with heart failure. Clinical Research in Cardiology, 2018, 107, 487-497.	3.3	22
517	Utilizing NT-proBNP for Eligibility and Enrichment in Trials in HFpEF, HFmrEF, and HFrEF. JACC: Heart Failure, 2018, 6, 246-256.	4.1	47
518	Heart failure with midâ€range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure, 2018, 20, 1230-1239.	7.1	295
519	Systolic Blood Pressure and Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. JAMA Cardiology, 2018, 3, 288.	6.1	93
520	Sex and Race Differences in Lifetime Risk of Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction. Circulation, 2018, 137, 1814-1823.	1.6	124

#	Article	IF	Citations
521	Gender-related differences in heart failure with preserved ejection fraction. Scientific Reports, 2018, 8, 1080.	3.3	60
522	Outcomes following heart failure hospitalization in a regional Australian setting between 2005 and 2014. ESC Heart Failure, 2018, 5, 271-278.	3.1	22
523	Negotiating renal dysfunction when treating patients with heart failure. Expert Review of Cardiovascular Therapy, 2018, 16, 113-122.	1.5	7
524	Causes and Temporal Patterns of 30â€Day Readmission Among Older Adults Hospitalized With Heart Failure With Preserved or Reduced Ejection Fraction. Journal of the American Heart Association, 2018, 7, .	3.7	33
525	Predictors of diastolic dysfunction in ethnic groups: observations from the Hypertensive Cohort of The Ethnic-Echocardiographic Heart of England Screening Study (E-ECHOES). Journal of Human Hypertension, 2018, 32, 477-486.	2.2	4
526	Associations With and Prognostic and Discriminatory Role of N-Terminal Proâ€"B-Type Natriuretic Peptide in Heart Failure With Preserved Versus Mid-range Versus Reduced Ejection Fraction. Journal of Cardiac Failure, 2018, 24, 365-374.	1.7	32
527	Incidence and predictors of 6â€¯months mortality after an acute heart failure event in rural Uganda: The Mbarara Heart Failure Registry (MAHFER). International Journal of Cardiology, 2018, 264, 113-117.	1.7	9
528	Identifying novel phenotypes of acute heart failure using cluster analysis of clinical variables. International Journal of Cardiology, 2018, 262, 57-63.	1.7	55
529	The Current Focus of Heart Failure Clinical Trials. Journal of Cardiac Failure, 2018, 24, 321-329.	1.7	4
530	Strategies to address the shortcomings of commonly used advanced chronic heart failure descriptors to improve recruitment in palliative care research: A parallel mixed-methods feasibility study. Palliative Medicine, 2018, 32, 517-524.	3.1	7
531	Lessons learned in acute heart failure. European Journal of Heart Failure, 2018, 20, 630-641.	7.1	33
532	Thromboembolisms in atrial fibrillation and heart failure patients with a preserved ejection fraction (HFpEF) compared to those with a reduced ejection fraction (HFrEF). Heart and Vessels, 2018, 33, 403-412.	1.2	25
533	Epidemiology of Left Ventricular SystolicÂDysfunction and Heart Failure inÂtheÂFramingham Study. JACC: Cardiovascular Imaging, 2018, 11, 1-11.	5.3	158
534	What's Next for Acute Heart Failure Research?. Academic Emergency Medicine, 2018, 25, 85-93.	1.8	11
535	Outcomes of de novo and acute decompensated heart failure patients according to ejection fraction. Heart, 2018, 104, 525-532.	2.9	36
536	Newer hormonal pharmacotherapies for heart failure. Expert Review of Endocrinology and Metabolism, 2018, 13, 35-49.	2.4	1
537	Acute Dyspnea and Decompensated Heart Failure. Cardiology Clinics, 2018, 36, 63-72.	2.2	12
538	Predictors and outcomes of heart failure with midâ€range ejection fraction. European Journal of Heart Failure, 2018, 20, 651-659.	7.1	91

#	Article	IF	Citations
539	Effect of Diabetes on the Assessment Role of 2-Oxoglutarate to the Severity of Chronic Heart Failure. Experimental and Clinical Endocrinology and Diabetes, 2018, 126, 478-486.	1.2	1
540	Circulating microRNAs as novel biomarkers for heart failure. Hellenic Journal of Cardiology, 2018, 59, 209-214.	1.0	44
541	Is the mean platelet volume a predictive marker of a high in-hospital mortality of acute cardiorenal syndrome patients receiving continuous renal replacement therapy?. Medicine (United States), 2018, 97, e11180.	1.0	8
542	Atrial fibrillation in heart failure syndromes: does it matter more in some than in others?. European Heart Journal, 2018, 39, 4285-4286.	2.2	4
543	The Vulnerable Phase of Heart Failure. American Journal of Therapeutics, 2018, 25, e456-e464.	0.9	25
544	Moving From Heart Failure Guidelines to Clinical Practice: Gaps Contributing to Readmissions in Patients With Multiple Comorbidities and Older Age. Clinical Medicine Insights: Cardiology, 2018, 12, 117954681880935.	1.8	33
545	Highâ€Sensitivity Troponin I in Hospitalized and Ambulatory Patients With Heart Failure With Preserved Ejection Fraction: Insights From the Heart Failure Clinical Research Network. Journal of the American Heart Association, 2018, 7, e010364.	3.7	22
546	Implementation of a Multidisciplinary Inpatient Cardiology Service to Improve Heart Failure Outcomes in Guyana. Journal of Cardiac Failure, 2018, 24, 835-841.	1.7	6
547	Association between loop diuretic dose administered in first 24 hours of heart failure admissions and length of hospital stay. Journal of Community Hospital Internal Medicine Perspectives, 2018, 8, 195-199.	0.8	0
548	Prevalence of co-morbid conditions in Heart failure: an experience at tertiary care hospital. Journal of Nobel Medical College, 2018, 6, 35-41.	0.1	0
549	Demographics, Management, and In-Hospital Outcome of Hospitalized Acute Heart Failure Syndrome Patients in Contemporary Real Clinical Practice in Japanã€€â€• Observations From the Prospective, Multicenter Kyoto Congestive Heart Failure (KCHF) Registry â€•. Circulation Journal, 2018, 82, 2811-2819.	1.6	90
550	A Critical Appraisal of Short-Term End Points in Acute Heart Failure Clinical Trials. Journal of Cardiac Failure, 2018, 24, 783-792.	1.7	11
551	Discharge home health services referral and 30-day all-cause readmission in older adults with heart failure. Archives of Medical Science, 2018, 14, 995-1002.	0.9	17
552	Is extensive atrial fibrosis in the setting of heart failure associated with a reduced atrial fibrillation burden?. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 1289-1297.	1.2	6
553	Hyperkalemia in Heart Failure: Probably Not Oâ€œKâ€• Journal of the American Heart Association, 2018, 7, .	3.7	10
554	Vascular extracellular vesicles in comorbidities of heart failure with preserved ejection fraction in men and women: The hidden players. A mini review. Vascular Pharmacology, 2018, 111, 1-6.	2.1	5
555	Stable but Progressive Nature of Heart Failure: Considerations for Primary Care Physicians. American Journal of Cardiovascular Drugs, 2018, 18, 333-345.	2.2	12
557	Rationale and Design of the Multicenter Trial on Japan Working Group on the Effects of Angiotensin Receptor Blockers Selection (Azilsartan vs. Candesartan) on Diastolic Function in the Patients Suffering from Heart Failure with Preserved Ejection Fraction: J-TASTE Trial. Cardiovascular Drugs and Therapy, 2018, 32, 381-388.	2.6	3

#	Article	IF	Citations
558	Use of Vasodilators in Heart Failure. , 2018, , 523-537.		0
559	HFpEF. JACC: Heart Failure, 2018, 6, 718-719.	4.1	8
560	Role of High-Dose Beta-Blockers in Patients with Heart Failure with Preserved Ejection Fraction and Elevated Heart Rate. American Journal of Medicine, 2018, 131, 1473-1481.	1.5	26
561	Sex Differences in Heart Failure. Advances in Experimental Medicine and Biology, 2018, 1065, 529-544.	1.6	43
562	Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview. Archives of Medical Science, 2018, 14, 890-909.	0.9	42
563	Heart Failure With Preserved Ejection Fraction. , 2018, , 209-215.		0
564	CSI position statement on management of heart failure in India. Indian Heart Journal, 2018, 70, S1-S72.	0.5	18
565	A step forward in resolving an old issue: treatment of heart failure with preserved ejection fraction and renal dysfunction?. European Journal of Preventive Cardiology, 2018, 25, 1263-1267.	1.8	2
566	Clinical Characteristics, Management, and Outcomes of Japanese Patients Hospitalized for Heart Failure With Preserved Ejection Fractionã€€â€• A Report From the Japanese Heart Failure Syndrome With Preserved Ejection Fraction (JASPER) Registry â€•. Circulation Journal, 2018, 82, 1534-1545.	1.6	72
567	Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials. JAMA Cardiology, 2018, 3, 1011.	6.1	146
568	Is the clinical presentation of chronic heart failure different in elderly versus younger patients and those with preserved versus reduced ejection fraction?. European Journal of Internal Medicine, 2018, 57, 61-69.	2.2	11
569	Heart failure with preserved ejection fraction in Asia. European Journal of Heart Failure, 2019, 21, 23-36.	7.1	102
570	Heart Failure with Mid-Range Ejection Fraction - State of the Art. Arquivos Brasileiros De Cardiologia, 2019, 112, 784-790.	0.8	12
571	Heart Failure in Sub-Saharan Africa. , 2019, , .		6
572	Cardiac resynchronization therapy in patients with heart failure and moderately reduced ejection fraction: Could it trigger a super-response?. Indian Heart Journal, 2019, 71, 229-234.	0.5	4
573	Vagus nerve stimulation for the treatment of heart failure. Bioelectronics in Medicine, 2019, 2, 43-54.	2.0	6
574	TACIT (High Sensitivity Troponin T Rules Out Acute Cardiac Insufficiency Trial). Circulation: Heart Failure, 2019, 12, e005931.	3.9	14
575	Clinical Characteristics and Long-Term Outcomes of Patients with Acute Decompensated Heart Failure with Mid-Range Ejection Fraction. International Heart Journal, 2019, 60, 862-869.	1.0	7

#	Article	IF	Citations
576	Long-term Prognostic Significance of Admission Tricuspid Regurgitation Pressure Gradient in Hospitalized Patients With Heart Failure With Preserved Ejection Fraction: A Report From the Japanese Real-World Multicenter Registry. Journal of Cardiac Failure, 2019, 25, 978-985.	1.7	12
577	Digoxin Discontinuation and Outcomes inÂPatients With HeartÂFailure With Reduced EjectionÂFraction. Journal of the American College of Cardiology, 2019, 74, 617-627.	2.8	36
578	Heart failure with midâ€range ejection fraction: characterization of patients from the PINNACLE RegistryÂ®. ESC Heart Failure, 2019, 6, 784-792.	3.1	43
579	A health economic evaluation of using N-terminal pro brain natriuretic peptide for the management of acute heart failure: A pilot study in an Indonesian tertiary referral hospital. Emergency Care Journal, 2019, 15, .	0.3	0
580	Renoprotective Benefit of Tolvaptan in Acute Decompensated Heart Failure Patients With Loop Diuretic-Resistant Status. Journal of Clinical Medicine Research, 2019, 11, 49-55.	1.2	5
581	Which factors are associated with length of stay in older patients with acute decompensated heart failure with preserved ejection fraction?: AURORA study. Geriatrics and Gerontology International, 2019, 19, 1084-1087.	1.5	12
582	Management of Acute Hypertensive Heart Failure. Heart Failure Clinics, 2019, 15, 565-574.	2.1	5
583	2019 ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized With HeartÂFailure. Journal of the American College of Cardiology, 2019, 74, 1966-2011.	2.8	222
584	Clinical profile and one-year survival of patients with heart failure with reduced ejection fraction: The largest report from India. Indian Heart Journal, 2019, 71, 242-248.	0.5	16
585	Noncardiac Versus Cardiac Mortality in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction. Journal of the American Heart Association, 2019, 8, e013441.	3.7	62
586	Effects of carvedilol therapy in patients with heart failure with preserved ejection fraction â€“ Results from the Croatian heart failure (CRO-HF) registry. Medicina ClÃnica (English Edition), 2019, 152, 43-49.	0.2	0
587	Hyponatremia at discharge is associated with adverse prognosis in acute heart failure syndromes with preserved ejection fraction: a report from the JASPER registry. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 623-633.	1.0	8
588	Comparison of Characteristics and 3-Year Outcomes in Patients With Acute Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction. Circulation Journal, 2019, 83, 347-356.	1.6	33
589	Different Impact of Changes in Left Ventricular Ejection Fraction Between Heart Failure Classifications in Patients With Acute Decompensated Heart Failure. Circulation Journal, 2019, 83, 584-594.	1.6	13
590	Prognostic impact of chronic obstructive pulmonary disease on adverse prognosis in hospitalized heart failure patients with preserved ejection fraction â€“ A report from the JASPER registry. Journal of Cardiology, 2019, 73, 459-465.	1.9	19
591	Heart Failure With Preserved EjectionÂFraction and Diabetes. Journal of the American College of Cardiology, 2019, 73, 602-611.	2.8	182
592	Osteopontin Promotes Left Ventricular Diastolic Dysfunction Through a Mitochondrial Pathway. Journal of the American College of Cardiology, 2019, 73, 2705-2718.	2.8	41
593	Rationale and design of the EMPERIALâ€Preserved and EMPERIALâ€Reduced trials of empagliflozin in patients with chronic heart failure. European Journal of Heart Failure, 2019, 21, 932-942.	7.1	40

#	Article	IF	Citations
594	Systolic Blood Pressure and OutcomesÂinÂPatients With HeartÂFailure With ReducedÂEjectionÂFraction. Journal of the American College of Cardiology, 2019, 73, 3054-3063.	2.8	50
595	Cardiorenal Syndrome. Cardiology Clinics, 2019, 37, 251-265.	2.2	88
596	Sudden death in heart failure with preserved ejection fraction and beyond: an elusive target. Heart Failure Reviews, 2019, 24, 847-866.	3.9	25
597	Digoxin Use and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction. American Journal of Medicine, 2019, 132, 1311-1319.	1.5	11
598	Model-Based Quantification of Left Ventricular Diastolic Function in Critically Ill Patients with Atrial Fibrillation from Routine Data: A Feasibility Study. Computational and Mathematical Methods in Medicine, 2019, 2019, 1-11.	1.3	1
599	Circadian Comparison of Heart Rate Variability Parameters in Patients with Decompensated Heart Failure. IFMBE Proceedings, 2019, , 103-107.	0.3	0
600	Heart Failure With Preserved Ejection Fraction In Perspective. Circulation Research, 2019, 124, 1598-1617.	4.5	500
601	Racial differences of heart failure with midrange ejection fraction (HFmrEF): a large urban centre-based retrospective cohort study in the USA. BMJ Open, 2019, 9, e026479.	1.9	3
602	Sex Specific Mechanisms of Myocardial Hypertrophy and Heart Failure. , 2019, , 291-318.		1
603	Prognostic Impact of Worsening Renal Function in Hospitalized Heart Failure Patients With Preserved Ejection Fraction: A Report From the JASPER Registry. Journal of Cardiac Failure, 2019, 25, 631-642.	1.7	8
604	Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm. JAMA Cardiology, 2019, 4, 515.	6.1	51
605	Characteristics and outcome of acute heart failure patients according to the severity of peripheral oedema. International Journal of Cardiology, 2019, 285, 40-46.	1.7	13
606	Clinical features of heart failure with midâ€range and preserved ejection fraction in octogenarians: Results of a multicentre, observational study. International Journal of Clinical Practice, 2019, 73, e13341.	1.7	4
607	Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction. Heart, 2019, 105, heartjnl-2018-314173.	2.9	81
608	Age-dependent differences in clinical phenotype and prognosis in heart failure with mid-range ejection compared with heart failure with reduced or preserved ejection fraction. Clinical Research in Cardiology, 2019, 108, 1394-1405.	3.3	30
609	Renal Mechanisms and Heart Failure. Updates in Hypertension and Cardiovascular Protection, 2019, , 101-121.	0.1	0
610	Heart Failure with Preserved Ejection Fraction: Time to Revisit the Stiff Heart. Cardiovascular Innovations and Applications, 2019, 3, .	0.3	1
611	Epidemiology and long-term outcome in outpatients with chronic heart failure in Northwestern Europe. Heart, 2019, 105, 1252-1259.	2.9	18

#	Article	IF	Citations
612	Non-cardiac comorbidities and mortality in patients with heart failure with reduced vs. preserved ejection fraction: a study using the Swedish Heart Failure Registry. Clinical Research in Cardiology, 2019, 108, 1025-1033.	3.3	63
614	Frequency and Clinical Characteristics of Heart Failure with Preserved Ejection Fraction Patients in a Tertiary Level Hospital. University Heart Journal, 2019, 15, 63-67.	0.0	0
615	Exercise oscillatory ventilation and prognosis in heart failure patients with reduced and midâ€range ejection fraction. European Journal of Heart Failure, 2019, 21, 1586-1595.	7.1	24
616	Predictors of Heart Failure Readmission in a High-Risk Primarily Hispanic Population in a Rural Setting. Journal of Cardiovascular Nursing, 2019, 34, 267-274.	1.1	6
617	Perceived Stress Among Patients With Heart Failure Who Have Low Socioeconomic Status. Journal of Cardiovascular Nursing, 2019, 34, E1-E8.	1.1	26
618	Rhythm Control Versus Rate Control in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction: Insights From Get With The Guidelinesâ€"Heart Failure. Journal of the American Heart Association, 2019, 8, e011560.	3.7	68
619	Anticoagulation in patients with atrial fibrillation and heart failure: Insights from the NCDR PINNACLEâ€AF registry. Clinical Cardiology, 2019, 42, 339-345.	1.8	15
620	Autonomic Neuromodulation Acutely Ameliorates Left Ventricular Strain in Humans. Journal of Cardiovascular Translational Research, 2019, 12, 221-230.	2.4	58
621	Treatment patterns of patients with acute heart failure who develop acute kidney injury. ESC Heart Failure, 2019, 6, 45-52.	3.1	15
622	Lowâ€level transcutaneous vagus nerve stimulation attenuates cardiac remodelling in a rat model of heart failure with preserved ejection fraction. Experimental Physiology, 2019, 104, 28-38.	2.0	45
623	Are there patients missing from community heart failure registers? An audit of clinical practice. European Journal of Preventive Cardiology, 2019, 26, 291-298.	1.8	8
624	Patients with HFpEF and HFmrEF have different clinical characteristics in Turkey: A multicenter observational study. European Journal of Internal Medicine, 2019, 61, 88-95.	2.2	15
625	Heart failure with preserved ejection fraction in Asia: the far side of the moon?. European Journal of Heart Failure, 2019, 21, 37-39.	7.1	6
626	Plasma Haptoglobin Level can Augment NT-proBNP to Predict Poor Outcome in Patients with Severe Acute Decompensated Heart Failure. Journal of Investigative Medicine, 2019, 67, 20-27.	1.6	5
627	Spironolactone and Outcomes in Older Patients with Heart Failure and Reduced Ejection Fraction. American Journal of Medicine, 2019, 132, 71-80.e1.	1.5	20
628	Effects of carvedilol therapy in patients with heart failure with preserved ejection fraction â€" Results from the Croatian heart failure (CRO-HF) registry. Medicina ClÃnica, 2019, 152, 43-49.	0.6	4
629	Association between atrial fibrillation and heart failure with different ejection fraction categories and its influence on outcomes. Acta Cardiologica, 2020, 75, 423-432.	0.9	8
630	Do Patients With Acute Heart Failure and Preserved Ejection Fraction Have Heart Failure at Follow-Up: Implications of the Framingham Criteria. Journal of Cardiac Failure, 2020, 26, 673-684.	1.7	5

#	Article	IF	Citations
631	ALDH2 rs671 polymorphism and the risk of heart failure with preserved ejection fraction (HFpEF) in patients with cardiovascular diseases. Journal of Human Hypertension, 2020, 34, 16-23.	2.2	19
632	Pharmacological treatment patterns in heart failure: a population-based cohort study. European Journal of Clinical Pharmacology, 2020, 76, 97-106.	1.9	1
633	Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure: Rationale and design of CONNECT-HF. American Heart Journal, 2020, 220, 41-50.	2.7	22
634	Heart Failure as a Consequence of Ischemic Heart Disease. , 2020, , 254-268.e6.		2
635	Management of Comorbidities in Heart Failure. , 2020, , 687-696.e2.		0
636	Relationship between self-care adherence, time perspective, readiness to change and executive function in patients with heart failure. Journal of Behavioral Medicine, 2020, 43, 1-11.	2.1	12
637	Prior Heart Failure Hospitalization and Outcomes in Patients with Heart Failure with Preserved and Reduced Ejection Fraction. American Journal of Medicine, 2020, 133, 84-94.	1.5	26
638	Efficacy and Safety of Tolvaptan in Patients More Than 90 Years Old With Acute Heart Failure. Journal of Cardiovascular Pharmacology and Therapeutics, 2020, 25, 47-56.	2.0	5
640	The Chronic stage. , 2020, , 135-147.		0
641	Global Differences in Characteristics, Precipitants, and Initial Management of Patients Presenting With Acute Heart Failure. JAMA Cardiology, 2020, 5, 401.	6.1	51
642	Heart Failure With Mid-range Ejection Fraction. Current Heart Failure Reports, 2020, 17, 1-8.	3.3	24
643	Heart failure with preserved ejection fraction: New approaches to diagnosis and management. Clinical Cardiology, 2020, 43, 145-155.	1.8	83
644	Risk Stratification in Advanced Heart Failure. , 2020, , 19-29.		0
645	Age at menarche and heart failure risk: The EPIC-NL study. Maturitas, 2020, 131, 34-39.	2.4	4
646	Contemporary approach to treating heart failure. Trends in Cardiovascular Medicine, 2020, 30, 507-518.	4.9	9
647	Study protocol for the PURSUIT-HFpEF study: a Prospective, Multicenter, Observational Study of Patients with Heart Failure with Preserved Ejection Fraction. BMJ Open, 2020, 10, e038294.	1.9	32
648	Effect and safety of oral Chinese patent medicine for heart failure. Medicine (United States), 2020, 99, e22754.	1.0	2
649	OX-HDL: A Starring Role in Cardiorenal Syndrome and the Effects of Heme Oxygenase-1 Intervention. Diagnostics, 2020, 10, 976.	2.6	7

#	Article	IF	Citations
650	Loop Diuretic Prescription and 30-DayÂOutcomes in Older Patients WithÂHeartÂFailure. Journal of the American College of Cardiology, 2020, 76, 669-679.	2.8	41
651	Pulmonary arterial hypertension and heart failure with preserved ejection fraction: are they so discordant?. Cardiovascular Diagnosis and Therapy, 2020, 10, 534-545.	1.7	5
652	Spectrum of heart failure in sub-Saharan Africa: data from a tertiary hospital-based registry in the eastern center of Burkina Faso. Pan African Medical Journal, 2020, 36, 30.	0.8	9
653	Red blood cell distribution width in addition to N-terminal prohormone of B-type natriuretic peptide concentration improves assessment of risk of cardiovascular events in adult patients with congenital heart disease. Archives of Cardiovascular Diseases, 2020, 113, 607-616.	1.6	2
654	Hypertension as a Road to Treatment of Heart Failure with Preserved Ejection Fraction. Current Hypertension Reports, 2020, 22, 82.	3.5	13
655	Trends in Left Ventricular Ejection Fraction for Patients With a New Diagnosis of Heart Failure. Circulation: Heart Failure, 2020, 13, e006743.	3.9	4
656	Alternative payment models and innovation: a case study of US health system adoption of a sacubitril/valsartan to treat acute decompensated heart failure. Journal of Medical Economics, 2020, 23, 1450-1460.	2.1	0
657	Cardiovascular Outcomes with Sacubitril-Valsartan in Heart Failure: Emerging Clinical Data . Therapeutics and Clinical Risk Management, 2020, Volume 16, 715-726.	2.0	10
658	Predictors of Mortality by Sex and Race in Heart Failure With Preserved Ejection Fraction: ARIC Community Surveillance Study. Journal of the American Heart Association, 2020, 9, e014669.	3.7	19
659	Diagnosis and Management of Patients with Heart Failure with Preserved Ejection Fraction (HFpEF): Current Perspectives and Recommendations . Therapeutics and Clinical Risk Management, 2020, Volume 16, 769-785.	2.0	16
660	Acute heart failure â€“ The â€˜realâ€™ Malaysian experience: An observational study from a single non-cardiac centre. Proceedings of Singapore Healthcare, 2021, 30, 218-224.	0.6	5
661	Nonâ€severe aortic regurgitation increases shortâ€term mortality in acute heart failure with preserved ejection fraction. ESC Heart Failure, 2020, 7, 3901-3909.	3.1	12
662	Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: A blueprint for clinical trial design. International Journal of Cardiology, 2020, 313, 76-82.	1.7	30
663	Impact of diabetes mellitus on mortality in patients with acute heart failure: a prospective cohort study. Cardiovascular Diabetology, 2020, 19, 49.	6.8	18
664	Exhaled breath acetone for predicting cardiac and overall mortality in chronic heart failure patients. ESC Heart Failure, 2020, 7, 1744-1752.	3.1	14
665	Noncardiac comorbidity clustering in heart failure: an overlooked aspect with potential therapeutic door. Heart Failure Reviews, 2022, 27, 767-778.	3.9	6
666	Efficacy and Safety of Inorganic Nitrate Versus Placebo Treatment in Heart Failure with Preserved Ejection Fraction. Cardiovascular Drugs and Therapy, 2020, 34, 503-513.	2.6	5
667	Role of a Brief Intensive Observation Area with a Dedicated Team of Doctors in the Management of Acute Heart Failure Patients: A Retrospective Observational Study. Medicina (Lithuania), 2020, 56, 251.	2.0	19

#	Article	IF	Citations
668	Left ventricular contractile performance and heart failure in patients with left ventricular ejection fraction more than 40%. Heart and Vessels, 2020, 35, 1689-1698.	1.2	3
669	Association of Prior Left Ventricular Ejection Fraction With Clinical Outcomes in Patients With Heart Failure With Midrange Ejection Fraction. JAMA Cardiology, 2020, 5, 1027.	6.1	18
670	Temporal trends in cause-specific readmissions and their risk factors in heart failure patients in Sweden. International Journal of Cardiology, 2020, 306, 116-122.	1.7	6
671	Heart failure with midâ€range ejection fraction: pro and cons of the new classification of Heart Failure by European Society of Cardiology guidelines. ESC Heart Failure, 2020, 7, 381-399.	3.1	31
672	Relationship between left ventricular ejection fraction and cardiovascular outcomes following hospitalization for heart failure: insights from the RELAXâ€AHFâ€2 trial. European Journal of Heart Failure, 2020, 22, 726-738.	7.1	21
673	Effect of Ultrafiltration on Sleep Apnea and Cardiac Function in End-Stage Renal Disease. American Journal of Nephrology, 2020, 51, 139-146.	3.1	9
674	Gender Differences in Risk Factors Associated With Pulmonary Artery Systolic Pressure, Heart Failure, and Mortality in Blacks: Jackson Heart Study. Journal of the American Heart Association, 2020, 9, e013034.	3.7	8
675	Catheter ablation of atrial fibrillation reduces heart failure rehospitalization in patients with heart failure with preserved ejection fraction. Journal of Cardiovascular Electrophysiology, 2020, 31, 682-688.	1.7	34
676	An overview of hypertension and cardiac involvement in Asia: Focus on heart failure. Journal of Clinical Hypertension, 2020, 22, 423-430.	2.0	27
677	Differential Prognostic Impact of Atrial Fibrillation in Hospitalized Heart Failure Patients With Preserved Ejection Fraction According to Coronary Artery Disease Statusã€€â€• Report From the Japanese Nationwide Multicenter Registry â€•. Circulation Journal, 2020, 84, 397-403.	1.6	9
678	Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future. Clinical Research in Cardiology, 2020, 109, 1079-1098.	3.3	74
679	Biomarkers of Inflammation in Heart Failure Patients with Reduced and Preserved Ejection Fractions: Multi-Ethnic Study of Atherosclerosis. Metabolism: Clinical and Experimental, 2020, 104, 154130.	3.4	0
680	Predictors of mortality, strategies to reduce readmission, and economic impact of acute decompensated heart failure: Results of the Vellore Heart Failure Registry. Indian Heart Journal, 2020, 72, 20-26.	0.5	8
681	Clinical and echocardiographic characteristics of patients with preserved versus mid-range ejection fraction. International Journal of Cardiovascular Imaging, 2021, 37, 503-508.	1.5	1
682	Prognostic value of the H₂FPEF score in patients undergoing transcatheter aortic valve implantation. ESC Heart Failure, 2021, 8, 461-470.	3.1	13
683	Heart Failure With Midrange Ejection Fractionâ€"What Is It, IfÂAnything?. Canadian Journal of Cardiology, 2021, 37, 585-594.	1.7	4
684	The predictive value of global longitudinal strain in patients with heart failure mid-range ejection fraction. Journal of Cardiology, 2021, 77, 509-516.	1.9	4
685	Timeâ€sensitive approach in the management of acute heart failure. ESC Heart Failure, 2021, 8, 204-221.	3.1	17

#	Article	IF	Citations
686	Heart failure in people with type 2 diabetes vs. those without diabetes: A retrospective observational study from South India. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021, 15, 39-43.	3.6	1
687	Complex and Potentially Harmful Medication Patterns in Heart Failure with Preserved Ejection Fraction. American Journal of Medicine, 2021, 134, 374-382.	1.5	14
688	Application value of myocardial work technology by non-invasive echocardiography in evaluating left ventricular function in patients with chronic heart failure. Quantitative Imaging in Medicine and Surgery, 2022, 12, 244-256.	2.0	6
689	Stage D Heart Failure With Preserved Ejection Fraction, Heart Transplantation, and Mechanical Circulatory Support. , 2021, , 276-289.		0
690	Brief intensive observation areas in the management of acute heart failure in elderly patients leading to high stabilisation rate and less admissions. Journal of Gerontology and Geriatrics, 2021, 69, 87-97.	0.5	6
691	Evaluation of Adherence to Guideline for Heart Failure with Reduced Ejection Fraction in Heart Failure with Preserved Ejection Fraction and with or without Atrial Fibrillation. Journal of Korean Medical Science, 2021, 36, e252.	2.5	1
692	Heart Failure With Preserved Ejection Fraction. , 2021, , 201-222.		0
693	Part 1: The Wider Considerations in Translating Heart Failure Guidelines. Current Cardiology Reviews, 2021, 17, e160721190003.	1.5	2
694	Clinical Characteristics of De Novo Heart Failure and Acute Decompensated Chronic Heart Failure: Are They Distinctive Phenotypes That Contribute to Different Outcomes?. Cardiac Failure Review, 2020, 7, e02.	3.0	11
695	Nicotinamide for the treatment of heart failure with preserved ejection fraction. Science Translational Medicine, 2021, 13, .	12.4	109
696	Î²-blocker and 1-year outcomes among patients hospitalized for heart failure with mid-range ejection fraction. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 140-148.	3.0	6
697	Narrative review: the holy grail: update on pharmacotherapy for heart failure with preserved ejection fraction. Annals of Translational Medicine, 2021, 9, 523-523.	1.7	1
698	Sex-Specific Differences in Heart Failure: Pathophysiology, Risk Factors, Management, and Outcomes. Canadian Journal of Cardiology, 2021, 37, 560-571.	1.7	40
699	Clonal haematopoiesis of indeterminate potential: intersections between inflammation, vascular disease and heart failure. Clinical Science, 2021, 135, 991-1007.	4.3	18
700	Evaluation of the Usage and Dosing of Guideline-Directed Medical Therapy for Heart Failure With Reduced Ejection Fraction Patients in Clinical Practice. Journal of Pharmacy Practice, 2021, , 089719002110048.	1.0	6
701	Environmental factors, winter respiratory infections and the seasonal variation in heart failure admissions. Scientific Reports, 2021, 11, 11292.	3.3	3
702	Vulnerable Phase of Acute Heart Failure and its Association with Hospital Readmissions Reduction Program. Current Problems in Cardiology, 2022, 47, 100904.	2.4	7
703	Heart Failure With Mid-range Ejection Fraction: A Distinctive Subtype or a Transitional Stage?. Frontiers in Cardiovascular Medicine, 2021, 8, 678121.	2.4	6

#	Article	IF	Citations
704	Epidemiological and clinical boundaries of heart failure with preserved ejection fraction. European Journal of Preventive Cardiology, 2022, 29, 1233-1243.	1.8	16
705	Treatment of Heart Failure With Mid-Range Ejection Fraction: A Summary of Current Evidence. Frontiers in Cardiovascular Medicine, 2021, 8, 653336.	2.4	3
706	Clinical assessment of endothelial function in heart failure with preserved ejection fraction: A metaâ€analysis with metaâ€regressions. European Journal of Clinical Investigation, 2021, 51, e13552.	3.4	11
707	High-Dose Nitroglycerin Bolus for Sympathetic Crashing Acute Pulmonary Edema: A Prospective Observational Pilot Study. Journal of Emergency Medicine, 2021, 61, 271-277.	0.7	4
708	Heart failure with preserved ejection fraction based on aging and comorbidities. Journal of Translational Medicine, 2021, 19, 291.	4.4	14
709	Myocardial Tissue Characterization in Heart Failure with Preserved Ejection Fraction: From Histopathology and Cardiac Magnetic Resonance Findings to Therapeutic Targets. International Journal of Molecular Sciences, 2021, 22, 7650.	4.1	17
710	Heart Failure With Mid-range Ejection Fraction: Every Coin Has Two Sides. Frontiers in Cardiovascular Medicine, 2021, 8, 683418.	2.4	6
711	Do we need a simplified model to predict outcomes in patients hospitalized with Acute Decompensated Heart Failure? Results from The Role of Sodium in Heart Failure Outcomes Prediction (â€˜SHOUT-PREDICTIONâ€™) study. Indian Heart Journal, 2021, 73, 458-463.	0.5	2
712	Right ventricular systolic and diastolic function in heart failure with preserved ejection fraction. Cor Et Vasa, 2021, 63, 295-303.	0.1	0
713	Heart Failure With Midrange Ejection Fraction: Prior Left Ventricular Ejection Fraction and Prognosis. Frontiers in Cardiovascular Medicine, 2021, 8, 697221.	2.4	9
714	Efficacy and safety of diuretics in heart failure with preserved ejection fraction: a scoping review. Heart, 2022, 108, 593-605.	2.9	3
715	Outcomes of patients with heart failure with preserved ejection fraction discharged on treatment with neurohormonal antagonists after an episode of decompensation. European Journal of Internal Medicine, 2021, 94, 73-84.	2.2	5
716	Blood pressure visitâ€toâ€visit variability and outcomes in patients with heart failure with preserved ejection fraction. ESC Heart Failure, 2021, 8, 3984-3996.	3.1	4
717	The Central Role of Left Atrium in Heart Failure. Frontiers in Cardiovascular Medicine, 2021, 8, 704762.	2.4	13
718	Estimating Incidence of Acute Heart Failure Syndromes in Japanã€€â€• An Analysis From the KUNIUMI Registry â€•. Circulation Journal, 2021, 85, 1860-1868.	1.6	14
719	Early Identification of Patients at Risk for Incident Heart Failure With Preserved Ejection Fraction: Novel Approach to Echocardiographic Trends. Journal of Cardiac Failure, 2021, 27, 942-948.	1.7	0
721	Heart failure with mid-range or mildly reduced ejection fraction. Nature Reviews Cardiology, 2022, 19, 100-116.	13.7	156
722	State-of-the-Art Review of Current Therapies for HFpEF: An Overview of Interatrial Septal Device Therapy in Heart Failure. Current Cardiology Reviews, 2021, 17, e230421189012.	1.5	1

#	Article	IF	Citations
723	Noninvasive Venous Waveform Analysis Correlates With Pulmonary Capillary Wedge Pressure and Predicts 30-Day Admission in Patients With Heart Failure Undergoing Right Heart Catheterization. Journal of Cardiac Failure, 2022, 28, 1692-1702.	1.7	3
724	Role of high-density lipoproteins in cardioprotection and in reverse remodeling: Therapeutic implications. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2021, 1866, 159022.	2.4	7
725	Causas de muerte en pacientes hospitalizados en servicios de medicina interna por insuficiencia cardÃaca segÃºn la fracciÃ³n de eyecciÃ³n. Registro RICA. Medicina ClÃnica, 2022, 158, 13-19.	0.6	4
727	Heart Failure with Preserved Ejection Fraction. , 2015, , 213-230.		2
728	Early Medical Management of Hospitalization for Heart Failure (HHF). , 2015, , 113-149.		1
729	The Significance of Myofilament Protein Citrullination in Heart Failure: Citrullination in Cardiovascular Diseases. , 2017, , 205-225.		2
730	Risk Factors for Mortality with Heart Failure. , 2012, , 56-71.		2
731	Diagnosis and Management of Acute Heart Failure Syndromes. , 2012, , 517-542.		9
732	Epidemiology and clinical characteristics of hospitalized elderly patients for heart failure with reduced, mid-range and preserved ejection fraction. Heart and Lung: Journal of Acute and Critical Care, 2020, 49, 495-500.	1.6	8
733	Administration of apo A-I (Milano) nanoparticles reverses pathological remodelling, cardiac dysfunction, and heart failure in a murine model of HFpEF associated with hypertension. Scientific Reports, 2020, 10, 8382.	3.3	13
734	Should treatment for heart failure with preserved ejection fraction differ from that for heart failure with reduced ejection fraction?. BMJ: British Medical Journal, 2010, 341, c4202-c4202.	2.3	8
735	Ten-year survival and factors associated with increased mortality in patients admitted for acute decompensated heart failure in Thailand. Singapore Medical Journal, 2020, 61, 320-326.	0.6	5
736	Exercise intolerance in heart failure with preserved ejection fraction: more than a heart problem. Journal of Geriatric Cardiology, 2015, 12, 294-304.	0.2	68
737	Current Medical and Social Issues for Hospitalized Heart Failure Patients in Japan and Factors for Improving Their Outcomesã€€â€• Insights From the REAL-HF Registry â€•. Circulation Reports, 2020, 2, 226-234.	1.0	7
738	Heart Failure and Preserved Left Ventricular Function: Long Term Clinical Outcome. PLoS ONE, 2012, 7, e41022.	2.5	13
739	SUrvey of Guideline Adherence for Treatment of Systolic Heart Failure in Real World (SUGAR): A Multi-Center, Retrospective, Observational Study. PLoS ONE, 2014, 9, e86596.	2.5	33
740	Effects of Beta-Blockers on Heart Failure with Preserved Ejection Fraction: A Meta-Analysis. PLoS ONE, 2014, 9, e90555.	2.5	73
741	The impact of heart rate on patients diagnosed with heart failure with mid-range ejection fraction. Anatolian Journal of Cardiology, 2018, 21, 68-74.	0.9	5

#	Article	IF	Citations
742	The Impact of Discharged Loop Diuretic Dose to Home Dose on Hospital Readmissions in Patients with Acute Decompensated Heart Failure: A Retrospective Cohort Study. Heart Surgery Forum, 2020, 23, E470-E474.	0.5	3
743	2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology, 2020, 25, 4083.	1.4	229
744	2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology, 2020, 25, 4083.	1.4	32
746	Epidemiology and Prognosis of Heart Failure. International Cardiovascular Forum Journal, 0, 10, .	1.1	5
748	Istaroxime, a potential anticancer drug in prostate cancer, exerts beneficial functional effects in healthy and diseased human myocardium. Oncotarget, 2017, 8, 49264-49274.	1.8	5
749	Heart Failure in North America. Current Cardiology Reviews, 2013, 9, 128-146.	1.5	54
750	Cardiac Rhythm Monitoring After Acute Decompensation for Heart Failure: Results from the CARRYING ON for HF Pilot Study. JMIR Research Protocols, 2016, 5, e62.	1.0	5
751	Prognosis following a diagnosis of heart failure and the role of primary care: a review of the literature. BJGP Open, 2017, 1, bjgpopen17X101013.	1.8	27
752	Heart failure with preserved ejection fraction: insights from recent clinical researches. Korean Journal of Internal Medicine, 2020, 35, 514-534.	1.7	10
754	Therapeutic interventions for heart failure with preserved ejection fraction: A summary of current evidence. World Journal of Cardiology, 2014, 6, 67.	1.5	17
755	Diagnostic and prognostic value of circulating microRNAs in heart failure with preserved and reduced ejection fraction. World Journal of Cardiology, 2015, 7, 843.	1.5	24
756	Predictors of mortality in patients hospitalized for congestive heart failure with left ventricular ejection fraction â‰¥ 40%. Cardiology Journal, 2015, 22, 382-390.	1.2	7
757	Short-term outcomes after hospital discharge in patients admitted with heart failure in Abeokuta, Nigeria : data from the Abeokuta Heart Failure Registry : cardiovascular topic. Cardiovascular Journal of Africa, 2014, 25, 217-223.	0.4	8
758	Risk factors and outcomes of acute kidney injury after intracoronary stent implantation. World Journal of Emergency Medicine, 2012, 3, 197.	1.0	9
759	Longitudinal Shortening of the Left Ventricle by Cine-CMR for Assessment of Diastolic Function in Patients with Aortic Valve Disease. Arquivos Brasileiros De Cardiologia, 2019, 114, 284-292.	0.8	3
760	Decreased Renal Function is Associated with Heart Failure Readmissions. Cureus, 2018, 10, e3122.	0.5	7
761	Impact of weight loss in patients with heart failure with preserved ejection fraction: results from the FLAGSHIP study. ESC Heart Failure, 2021, 8, 5293-5303.	3.1	13
762	Clinical characteristics and correlates of patients with heart failure with mid-range ejection fraction in southwest Nigeria. Annals of Clinical and Biomedical Research, 2021, 2, .	0.1	0

#	Article	IF	Citations
763	Body composition analysis in patients with acute heart failure: the Scale Heart Failure trial. ESC Heart Failure, 2021, 8, 4593-4606.	3.1	7
764	Drug Layering in HeartÂFailure. JACC: Heart Failure, 2021, 9, 775-783.	4.1	32
765	Cardiovascular Pharmacology. , 2011, , 235-295.		2
769	Acute decompensated heart failure. What are we missing?. The Bangkok Medical Journal, 2012, 03, 79-88.	0.0	0
770	Heart Failure with Preserved Ejection Fraction. Suez Canal University Medical Journal, 2012, 15, 1-13.	0.0	0
771	The pathophysiology of AHF â€"New insights from recent studies of novel diuretics and vascular modulating therapies</br>. World Journal of Cardiovascular Diseases, 2013, 03, 133-145.	0.2	0
772	Diagnosis and Management of Acute Heart Failure. , 2014, , 238-254.		1
773	Dying from Cardiovascular Disease: An Epidemiologic Perspective. , 2015, , 1-20.		0
774	Impact of QRS Duration in Heart Failure with Preserved Ejection Fraction. Journal of Cardiovascular Disease, 2015, 3, .	0.5	0
776	A Retrospective Study of the Treatment Outcome of Drug Therapies used in Heart Failure Patients with Associated Co-morbidities in a Tertiary Care Hospital. Journal of Clinical and Diagnostic Research JCDR, 2016, 10, FC06-9.	0.8	2
777	Acute Heart Failure Syndromes. , 2017, , 81-162.		0
778	Observation Unit Admission Inclusion and Exclusion Criteria. Contemporary Cardiology, 2017, , 187-195.	0.1	0
779	Acute Decompensated Heart Failure: Presentation, Physical Exam, and Laboratory Evaluation. , 2017, , 171-193.		0
780	Acute Decompensated Heart Failure: Treatment â€" Specific Therapies. , 2017, , 219-284.		0
781	Acute Decompensated Heart Failure: Classification, Epidemiology and Pathophysiology. , 2017, , 149-170.		2
782	Heart Failure with Normal Left Ventricular Ejection Fraction (HFNEF). , 2017, , 273-339.		0
783	Acute Decompensated Heart Failure: Treatment Guidelines. , 2017, , 195-218.		1
784	Acute decompensated heart failure with preserved ejecton fraction: focus on serelaxin. Kardiologiya I Serdechno-Sosudistaya Khirurgiya, 2017, 10, 26.	0.3	0

#	Article	IF	Citations
785	Acute Decompensated Heart Failure: Treatment with Guideline Directed Medical Therapy and Discharge Planning. , 2017, , 285-308.		0
786	Cardiorenal Syndrome (CRS). , 2017, , 371-401.		0
787	The importance of chronic kidney disease for the assessment of risk of adverse outcomes after myocardial infarction. Klinicheskaia Meditsina, 2017, 95, 563-570.	0.1	1
788	Renal congestion related to worsening renal function in patients with acute decompensated heart failure: Diuretic strategy for acute cardiorenal syndrome. Archives of Clinical Nephrology, 0, , 012-017.	0.1	0
789	Chronotropic Incompetence As Pathophysiological Mechanism Reduction of Exercise Tolerance in Patients with Arterial Hypertension and Clinical Signs of Heart Failure with Preserved Left Ventricular Ejection Fraction. Family Medicine, 2018, .	0.1	0
790	Outcomes
of long-term observation period in patients with myocardial infarction undergone radiopaque interventions in the acute period of the
disease.. Klinicheskaia Meditsina, 2018, 96, 648-657.	0.1	0
791	Heart failure with preserved ejection fraction: phantom or real independent syndrome with Â«own faceÂ»?. UMJ Heart & Vessels, 2018, .	0.0	0
793	Demographics of patients â‰¥ 80 years with heart failure who were admitted to the cardiology clinics in Turkey. Anatolian Journal of Cardiology, 2019, 21, 196-205.	0.9	1
794	Towards tailoring blood pressure control in HFpEF: Lessons from OPTIMIZE-HF. Global Cardiology Science & Practice, 2019, 2019, 3.	0.4	0
795	A Patient with Chronic Kidney Disease and Heart Failure with Preserved. , 2020, , 89-106.		0
796	The Clinical Problem: Heart Failure Syndromes and their Epidemiology. International Cardiovascular Forum Journal, 0, 17, .	1.1	1
797	Heart Failure and the Obesity Paradox. , 2020, , 427-435.		0
798	The clinical characteristics of acute heart failure patients with mid-range ejection fraction in Turkey: A subgroup analysis from journey HF-TR study. International Journal of the Cardiovascular Academy, 2020, 6, 5.	0.2	0
799	Prognostic Significance of Diastolic Dysfunction With Multiple Comorbidities in Heart Failure Patients. Cureus, 2020, 12, e8297.	0.5	2
800	Feasibility of sacubitril/valsartan initiation early after acute decompensated heart failure. Cardiology Journal, 2020, 27, 625-632.	1.2	2
801	Predictive Value of HFA-PEFF Score in Patients With Heart Failure With Preserved Ejection Fraction. Frontiers in Cardiovascular Medicine, 2021, 8, 656536.	2.4	13
802	Locomotor Muscle Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction. Hypertension, 2021, 78, 1750-1759.	2.7	5
803	Frequency and clinical impact of hyperkalaemia within a large, modern, realâ€world heart failure population. ESC Heart Failure, 2021, 8, 691-696.	3.1	2

#	Article	IF	Citations
804	Do patients with heart failure and preserved, mid-range or reduced ejection fraction have different outcomes?. Cor Et Vasa, 2020, 62, 567-573.	0.1	1
805	Prognostic Significance of Post-Procedural Left Ventricular Ejection Fraction Following Atrial Fibrillation Ablation in Patients With Systolic Dysfunction. Circulation Reports, 2020, 2, 707-714.	1.0	10
806	PREDISCHAGE LUNG ULTRASOUND AS A PREDICTOR OF REHOSPITALIZATION OR MORTALITY ACUTE HEART FAILURE PATIENTS. International Journal of Research Science & Management, 2020, 7, 28-34.	0.0	0
807	Effect of Angiotensin Receptor-Neprilysin Inhibitor versus Valsartan on Cardiac Status in Patients with Chronic Heart Failure with Reduced Ejection Fraction: A Randomized Clinical Trial in Rangpur Medical College Hospital, Bangladesh. Open Journal of Internal Medicine, 2020, 10, 21-34.	0.2	1
808	Characteristics and Clinical Outcomes in Patients With Heart Failure With Preserved Ejection Fraction Compared to Heart Failure With Reduced Ejection Fraction: Insights From the VCOR Heart Failure Snapshot. Heart Lung and Circulation, 2022, 31, 623-628.	0.4	10
809	Spironolactone to improve exercise tolerance in people with permanent atrial fibrillation and preserved ejection fraction: the IMPRESS-AF RCT. Efficacy and Mechanism Evaluation, 2020, 7, 1-42.	0.7	2
811	Diagnosis and Management of Acute Heart Failure. , 2021, , 497-515.		0
812	DEFEAT - Heart Failure: a guide to management of geriatric heart failure by generalist physicians. Minerva Medica, 2009, 100, 39-50.	0.9	13
813	Influence of myocardial ischemia on outcomes in patients with systolic versus non-systolic heart failure. American Journal of Cardiovascular Disease, 2011, 1, 167-75.	0.5	3
814	Prognostic Factors for Survival at 6-Month Follow-up of Hospitalized Patients with Decompensated Congestive Heart Failure. ARYA Atherosclerosis, 2010, 6, 112-7.	0.4	7
815	Heart failure with preserved ejection fraction. Journal of Geriatric Cardiology, 2013, 10, 369-76.	0.2	16
816	Management of Chronic Heart Failure in Primary Care: What Evidence do we have for Heart Failure with Preserved Systolic Function?. Malaysian Family Physician, 2010, 5, 68-76.	0.6	1
817	Short-term prognostic factors in the patients after acute heart failure. International Journal of Clinical and Experimental Medicine, 2015, 8, 1515-20.	1.3	2
818	Worse Prognosis in Heart Failure Patients with 30-Day Readmission. Acta Cardiologica Sinica, 2016, 32, 698-707.	0.2	20
819	One-Year Outcomes of Acute Decompensated Systolic Heart Failure in Taiwan: Lessons from TSOC-HFrEF Registry. Acta Cardiologica Sinica, 2017, 33, 127-138.	0.2	33
820	Beta-blocker treatment in heart failure patients with atrial fibrillation: challenges and perspectives. Journal of Geriatric Cardiology, 2021, 18, 362-375.	0.2	1
821	Common Comorbidities that Alter Heart Failure Prognosis - Shaping New Thinking for Practice. Current Cardiology Reviews, 2021, 17, e160721187934.	1.5	3
822	Initiation of Anti-Hypertensive Drugs and Outcomes in Patients with Heart Failure with Reduced Ejection Fraction. American Journal of Medicine, 2022, 135, 737-744.	1.5	2

#	Article	IF	Citations
823	Incidence and Outcomes of Acute Heart Failure With Preserved Versus Reduced Ejection Fraction in SPRINT. Circulation: Heart Failure, 2021, 14, CIRCHEARTFAILURE121008322.	3.9	9
824	Phenotyping congestion in patients with acutely decompensated heart failure with preserved and reduced ejection fraction: The Decongestion duRing therapY for acute decOmpensated heart failure in HFpEF vs HFrEF- DRY-OFF study. European Journal of Internal Medicine, 2022, 97, 69-77.	2.2	12
825	Management, survival, and predictors of mortality among hospitalized heart failure patients at Debre Markos comprehensive specialized hospital, Northwest Ethiopia: Prospective cohort study. SAGE Open Medicine, 2021, 9, 205031212110573.	1.8	3
826	SERELAXIN IN THE STRATEGY OF MANAGEMENT THE PATIENTS WITH ACUTE DECOMPENSATED HEART FAILURE: FROM DECREASING OF SYMPTOMS TO THE IMPROVEMENT OF SURVIVAL. Eurasian Heart Journal, 2015, , 32-37.	0.8	1
827	Causes of death in hospitalized patients in internal medicine departments with heart failure according to ejection fraction. RICA registry. Medicina ClÃnica (English Edition), 2022, 158, 13-19.	0.2	0
828	A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fractionÂâ€“Âinsights from the <scp>ESCâ€HFA EORP</scp> Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2022, 24, 335-350.	7.1	49
829	Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovascular Research, 2023, 118, 3272-3287.	3.8	517
831	Improving the EHMRG Prognostic Evaluation of Acute Heart Failure with TAPSE/PASp: A Sequential Approach. Diagnostics, 2022, 12, 478.	2.6	2
832	Left ventricular systolic function affects right atrial pressure as prognosticator in patients with heart failure. International Journal of Cardiovascular Imaging, 2022, 38, 1671-1682.	1.5	0
833	The Prognostic Value of Anemia in Patients with Preserved, Mildly Reduced and Recovered Ejection Fraction. Diagnostics, 2022, 12, 517.	2.6	7
834	Incidence and prognostic value of acute kidney injury in pulmonary embolism: data from the SIRENA registry. Russian Journal of Cardiology, 2022, 27, 4864.	1.4	0
835	Lifestyle and Cardiovascular Risk FactorsÂAssociated With HeartÂFailure Subtypes in Postmenopausal Breast CancerÂSurvivors. JACC: CardioOncology, 2022, 4, 53-65.	4.0	16
836	Baseline characteristics of outpatients with heart failure according to phenotype: preliminary analysis from SMYRNA-HF registry. The European Research Journal, 2022, 8, 266-274.	0.3	1
837	In-Hospital Weight Loss and Outcomes in Patients With Heart Failure. Journal of Cardiac Failure, 2022, 28, 1116-1124.	1.7	2
838	Empagliflozin in patients hospitalized for acute decompensated heart failure: an expert resolution on the discussion of the EMPULSE trial. Russian Journal of Cardiology, 2022, 27, 4945.	1.4	1
844	Predictors of thirty-day readmission in nonagenarians presenting with acute heart failure with preserved ejection fraction: a nationwide analysis.. Journal of Geriatric Cardiology, 2021, 18, 1008-1018.	0.2	1
846	Management strategies in heart failure with preserved ejection fraction. Herz, 2022, 47, 332-339.	1.1	2
847	Diastolic Function. , 2016, , 173-197.		0

#	Article	IF	Citations
848	From mid-range to mildly reduced ejection fraction heart failure: A call to treat. European Journal of Internal Medicine, 2022, 103, 29-35.	2.2	5
849	Toward a Better Understanding of the Differential Impact of Heart Failure Phenotypes After Breast Cancer. Journal of Clinical Oncology, 2022, 40, 3688-3691.	1.6	4
850	Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction. BMC Cardiovascular Disorders, 2022, 22, .	1.7	4
852	Breakthroughs in the treatment of heart failure with mildly reduced and preserved ejection fraction. Clinical Cardiology, 2022, 45, .	1.8	8
853	Guideline-directed medical therapy is similarly effective in heart failure with mildly reduced ejection fraction. Clinical Research in Cardiology, 2023, 112, 111-122.	3.3	8
854	Current Understanding of Molecular Pathophysiology of Heart Failure With Preserved Ejection Fraction. Frontiers in Physiology, 0, 13, .	2.8	13
855	What dietary interventions have been tested in heart failure with preserved ejection fraction? A systematic scoping review. European Journal of Cardiovascular Nursing, 2023, 22, 126-140.	0.9	3
856	Heart failure with reduced, mildly reduced, or preserved left ventricular ejection fraction: Has reasoning been lost?. World Journal of Cardiology, 2022, 14, 438-445.	1.5	4
857	Cardiovascular diseases and diabetes mellitus. The European Research Journal, 2022, 8, 541-549.	0.3	1
858	Heart failure with mildly reduced ejection fraction: from diagnosis to treatment. Gaps and dilemmas in current clinical practice. Heart Failure Reviews, 0, , .	3.9	4
859	Benefits of tolvaptan on early dyspnea relief in patients with acute heart failure: A metaâ€analysis. Clinical Cardiology, 0, , .	1.8	6
860	The circular pathway for the improvement of readmitting heart failure patients. International Journal of Cardiology, 2022, 365, 85-86.	1.7	0
861	CHRONIC HEART DEFICIENCY WITH PRESERVED LEFT VENTRICLE EJECTION FRACTION (literature review). Problemy ZdorovÊ¹Ã¢ I Ã¨kologii, 2012, , 7-11.	0.1	1
862	Validation of the MEDIA echo score for the prognosis of heart failure with preserved ejection fraction. Heart Failure Reviews, 0, , .	3.9	0
864	Clinical characteristics of heart failure patients with mid-range ejection fraction. Acta Cardiologica, 2023, 78, 233-240.	0.9	2
865	Sexâ€based differences in referral of heart failure patients to outpatient clinics: a scoping review. ESC Heart Failure, 2022, 9, 3702-3712.	3.1	3
866	Empagliflozin Preserves Skeletal Muscle Function in a HFpEF Rat Model. International Journal of Molecular Sciences, 2022, 23, 10989.	4.1	10
867	Proteomic Analysis of Effects of Spironolactone in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2022, 15, .	3.9	7

#	Article	IF	Citations
868	Emergency department risk assessment and disposition of acute heart failure patients: existing evidence and ongoing challenges. Heart Failure Reviews, 2023, 28, 781-793.	3.9	4
869	Association between class of foundational medication for heart failure and prognosis in heart failure with reduced/mildly reduced ejection fraction. Scientific Reports, 2022, 12, .	3.3	0
870	Cardiovascular magnetic resonance phenotyping of heart failure with mildly reduced ejection fraction. European Heart Journal Cardiovascular Imaging, 2022, 24, 38-45.	1.2	4
871	Association between tricuspid annular systolic velocity and poor short-term prognosis in patients with acute decompensated heart failure. Annals of Medicine, 2022, 54, 2897-2907.	3.8	1
872	A retrospective study on the clinical significance of cardiac computed tomography in heart failure patients with preserved ejection fraction. Annals of Translational Medicine, 2022, .	1.7	0
873	Diastolic Heart Failure: What, So What and Now What?. Annals of the Academy of Medicine, Singapore, 2009, 38, 663-666.	0.4	0
874	The novel inflammatory biomarker GlycA and triglyceride-rich lipoproteins are associated with the presence of subclinical myocardial dysfunction in subjects with type 1 diabetes mellitus. Cardiovascular Diabetology, 2022, 21, .	6.8	5
875	Efficacy of guidelineâ€directed medical treatment in heart failure with mildly reduced ejection fraction. ESC Heart Failure, 2023, 10, 1035-1042.	3.1	3
876	Unplanned 30-day readmissions, comorbidity and impact on one-year mortality following incident heart failure hospitalisation in Western Australia, 2001â€“2015. BMC Cardiovascular Disorders, 2023, 23, .	1.7	1
877	A Comparison of Readmission Rates in Heart Failure with Preserved Ejection Fraction (HFpEF) V/S Heart Failure with Reduced Ejection Fraction (HFrEF). , 0, , 137-141.		0
878	Acute Heart Failure: Diagnosticâ€“Therapeutic Pathways and Preventive Strategiesâ€”A Real-World Cliniciana€™s Guide. Journal of Clinical Medicine, 2023, 12, 846.	2.4	4
879	Pathophysiology-Based Management of Acute Heart Failure. Clinics and Practice, 2023, 13, 206-218.	1.4	1
880	Long-Term Prognosis of Patients with Heart Failure: Follow-Up Results of Journey HF-TR Study Population. Anatolian Journal of Cardiology, 2023, 27, 26-33.	0.9	0
881	Clinical Value of Novel Echocardiographic Biomarkers Assessing Myocardial Work in Acute Heart Failureâ€”Rationale and Design of the â€œBeyond Myo-HF Studyâ€• Diagnostics, 2023, 13, 1191.	2.6	0
882	Heart Failure with Preserved vs. Reduced Ejection Fraction: Patient Characteristics, In-hospital Treatment and Mortalityâ€”DanAHF, a Nationwide Prospective Study. Journal of Cardiovascular Translational Research, 0, , .	2.4	0
883	Renal Denervation Helps Preserve the Ejection Fraction by Preserving Endocardial-Endothelial Function during Heart Failure. International Journal of Molecular Sciences, 2023, 24, 7302.	4.1	1
885	Heart Failure With Stable Mildly-reduced Ejection Fraction: Prognosis and Predictors of Outcomes. Current Problems in Cardiology, 2023, 48, 101631.	2.4	3
886	Time to Triple Therapy in Patients With de Novo Heart Failure With Reduced Ejection Fraction: a Population-Based Study. Journal of Cardiac Failure, 2023, 29, 719-729.	1.7	2

#	Article	IF	Citations
887	From Primary to Tertiary Care: Expert Position Statements to Guide Heart Failure with Preserved Ejection Fraction Diagnosis. The Malaysian Journal of Medical Sciences, 2023, 30, 49-66.	0.5	0
888	Association between changes in loop diuretic dose and outcomes in acute heart failure. ESC Heart Failure, 2023, 10, 1757-1770.	3.1	2
889	Comparison of Efficacy and Safety of Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis. Cureus, 2023, , .	0.5	0
890	Arterial stiffness and its associations with left ventricular diastolic function according to heart failure types. Clinical Hypertension, 2023, 29, .	2.0	0
891	Management of Heart Failure with Reduced Ejection Fraction Globally and in Lebanon: Where Do SGLT-2is Stand?. World Journal of Cardiovascular Diseases, 2023, 13, 138-169.	0.2	0
892	Treatment Strategies of Improving Quality of Care in Patients With Heart Failure. Korean Circulation Journal, 2023, 53, 294.	1.9	4
893	Renin-Angiotensin Inhibition and Outcomes in HFrEF and Advanced Kidney Disease. American Journal of Medicine, 2023, 136, 677-686.	1.5	2
894	Challenges and opportunities for increasing patient involvement in heart failure self-care programs and self-care in the postâ€“hospital discharge period. Research Involvement and Engagement, 2023, 9, .	2.9	1
895	Characteristics and in-hospital mortality of elderly patients with heart failure in Spanish hospitals. Journal of Geriatric Cardiology, 2023, 20, 247-255.	0.2	1
896	Guideline-Directed Medical Therapy for the Treatment of Heart Failure with Reduced Ejection Fraction. Drugs, 2023, 83, 747-759.	10.9	2
897	Ejection fraction at hospital admission stratifies mortality risk in HFmrEF patients aged â‰¥â€‰70Âyears: a retrospective analysis from a tertiary university institution. Aging Clinical and Experimental Research, 2023, 35, 1679-1693.	2.9	0
899	An Assessment of Cardiovascular Functional Capacity of a Group of Chronic Heart Failure Patients Using the 6-Minute Walk Test in a Cameroonian Urban Setting. World Journal of Cardiovascular Diseases, 2023, 13, 275-282.	0.2	0
900	Acute heart failure with mildly reduced ejection fraction and myocardial infarction: a multi-institutional cohort study. BMC Cardiovascular Disorders, 2023, 23, .	1.7	1
901	Incidence and prevalence of heart failure in England: a descriptive analysis of linked primary and secondary care data â€“ the PULSE study. BMC Cardiovascular Disorders, 2023, 23, .	1.7	1
902	Global Public Health Burden of Heart Failure: An Updated Review. Cardiac Failure Review, 0, 9, .	3.0	12
903	Heart Failure with Preserved Left Ventricular Ejection Fraction: A Complex Conundrum Simply Not Limited to Diastolic Dysfunction. Cardiovascular Therapeutics, 2023, 2023, 1-18.	2.5	2
905	Independent prognostic value of the congestion and renal index in patients with acute heart failure. Journal of Geriatric Cardiology, 2023, 20, 516-526.	0.2	0
906	The link between obesity and agingÂ-Âinsights into cardiac energy metabolism. Mechanisms of Ageing and Development, 2023, 216, 111870.	4.6	0

#	Article	IF	Citations
907	Heart Failure: Recent Advances and Breakthroughs. Disease-a-Month, 2024, 70, 101634.	1.1	0
908	Missed opportunities in the diagnosis of heart failure: a realâ€world assessment. ESC Heart Failure, 0, , .	3.1	0
909	Calcium channel blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction. European Journal of Heart Failure, 2023, 25, 2202-2214.	7.1	3
910	Role of ejection fraction in patients at risk for advanced heart failure: insights from the HELPâ€HF registry. ESC Heart Failure, 0, , .	3.1	0
911	Non-invasive technologies for heart failure, systolic and diastolic dysfunction modeling: a scoping review. Frontiers in Bioengineering and Biotechnology, 0, 11, .	4.1	1
912	Prognostic impact of acute decompensated heart failure in patients with heart failure with mildly reduced ejection fraction. European Heart Journal: Acute Cardiovascular Care, 2024, 13, 225-241.	1.0	3
913	The Optimal Management of Patients with Atrial Fibrillation and Acute Heart Failure in the Emergency Department. Medicina (Lithuania), 2023, 59, 2113.	2.0	1
914	Immunizing hearts: exploring the vaccination frontier in heart failure management. Annals of Medicine and Surgery, 2024, 86, 300-307.	1.1	0
915	Assessment of Troponin I Levels as a Predictor of Mortality in Acute Decompensated Heart Failure. Cureus, 2023, , .	0.5	0
916	In-hospital complications after MitraClip in patients with heart failure and preserved versus reduced ejection fraction in the United States. Cardiovascular Revascularization Medicine, 2023, , .	0.8	0
917	Assessing the prognostic significance of mean pulmonary artery velocity in heart failure with slightly reduced ejection fraction. Current Problems in Cardiology, 2024, 49, 102238.	2.4	0
918	Effects of Dapagliflozin in Patients in Asia. JACC Asia, 2024, 4, 108-118.	1.5	1
919	Resource utilisation and outcomes of people with heart failure in England: a descriptive analysis of linked primary and secondary care data â€“ the PULSE study. Open Heart, 2023, 10, e002467.	2.3	0
920	Epidemiology, Clinical Characteristics and Cause-specific Outcomes in Heart Failure with Preserved Ejection Fraction. Cardiac Failure Review, 0, 9, .	3.0	0
921	Akute Herzinsuffizienz und kardiale Dekompensation. Springer Reference Medizin, 2023, , 323-339.	0.0	0
922	Clinical Review of Hypertensive Acute Heart Failure. Medicina (Lithuania), 2024, 60, 133.	2.0	0
923	Sex differences in the nutritional status and its association with long-term prognosis in patients with heart failure with reduced ejection fraction: a prospective cohort study. European Journal of Cardiovascular Nursing, 0, , .	0.9	2
924	Revascularization for Patients With Heart Failure With Preserved Ejection Fraction and Coronary Artery Disease. American Journal of Cardiology, 2024, 213, 86-92.	1.6	0

#	Article	IF	Citations
925	Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodiumâ€"Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure. International Journal of Molecular Sciences, 2024, 25, 2484.	4.1	0
926	Prognostic significance of left atrial strain combined with left ventricular strain using cardiac magnetic resonance feature tracking in patients with heart failure with preserved ejection fraction. Heart and Vessels, 2024, 39, 404-411.	1.2	0
927	Burden from Study Questionnaire on Patient Fatigue in Qualitative Congestive Heart Failure Research. Journal of Cardiovascular Development and Disease, 2024, 11, 96.	1.6	0
928	Acute Heart Failure. Cardiology Clinics, 2024, 42, 165-186.	2.2	0
929	Leucine Supplementation Prevents the Development of Skeletal Muscle Dysfunction in a Rat Model of HFpEF. Cells, 2024, 13, 502.	4.1	0